VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 24 (23–31 octubre/2026)



EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Noticias en la Web

The demand for meningococcal disease vaccines is increasing



Oct 23. Every morning, the Dong Nai Center for Disease Control (CDC) is crowded with people registering for various vaccinations. Ms. Dang Thi Toan (Long Binh ward) said that she heard about the many cases of meningococcal disease and knew it was quite dangerous, so this morning she took her over 9-year-old daughter to get vaccinated against meningococcal disease BC.

Sharing the same concern, Ms. Nguyen Thi Thanh Chi (Tan An commune) also took her 6-month-old child to receive the first dose of the meningococcal vaccine. Ms. Chi said: Although the cost of the meningococcal vaccine is quite high, in return, she and her husband feel reassured. Because if their child were to contract the disease, the impact on their health and the cost of care and treatment would be much more expensive.

According to statistics from the Dong Nai CDC, in the past two weeks, the demand for meningococcal vaccine at the center has increased significantly, averaging about 10 doses per day, compared to only 2-3 doses per day previously.

At Dong Nai Hospital -2, Dr. Nguyen Quoc Ky, Head of the Vaccination Unit, said: In recent days, the unit has recorded a doubling of the number of people getting meningococcal vaccines compared to before, with 10-15 doses per day, sometimes up to 17 doses/day. To meet the sudden surge in demand for vaccines, the hospital has imported more than 200 additional doses of meningococcal vaccine.

Dr. Le Thi Hong, from the Vietnam National Vaccination Center for Children and Adults (VNVC) in Dong Nai, stated: People need to receive all the necessary vaccines against the five serotypes of meningococcal bacteria to ensure comprehensive protection. The meningococcal vaccines for groups B, A, C, Y, and W can be administered in the same vaccination session at two different locations and combined with other vaccines, making it convenient for people to complete their vaccination schedule and prevent the disease early.

Warning signs of meningococcal disease

Dr. Pham Thi Kieu Trang, Head of the Intensive Care and Toxicology Department (Dong Nai Children's Hospital), warns: Meningococcal meningitis is one of the infectious diseases that can progress rapidly and is dangerous. In the fulminant form, patients can fall into a critical condition and die within 24 hours of symptom onset. Some cases of fulminant septicemia can be fatal in just 6-8 hours if not detected, treated, and managed promptly.

Experts note that when meningococcal bacteria enter the bloodstream, they trigger a series of inflammatory responses. Patients can quickly develop respiratory failure, kidney failure, meningitis, subcutaneous hemorrhage, vascular necrosis, and many other life-threatening complications. In particular, initial symptoms such as fever, headache, nausea, fatigue, or body aches are easily

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

mistaken for common infections. The characteristic purpura may appear late or be unclear in the early stages, making it difficult for patients and their families to recognize the severity and seek timely medical attention.

Fuente: VIETNAM.VN. Disponible en https://n9.cl/j8emgb

Pfizer presenta resultados detallados por serotipos de un ensayo de fase II con su candidata a vacuna antineumocócica conjugada 25-valente PF-07872412 en lactantes



24 oct. Pfizer ha presentado resultados detallados por serotipos de un ensayo de fase II (NCT06524414) con su candidata a vacuna antineumocócica conjugada 25-valente en fase de investigación, PF-07872412 (25vPnC), en lactantes. En el estudio, una pauta de cuatro dosis de 25vPnC indujo respuestas inmunitarias sólidas frente a los 25 serotipos y demostró una seguridad y tolerabilidad comparables a las de cuatro dosis de PREVNAR 20® (vacuna antineumocócica conjugada 20-valente). El ensayo de fase II evalúa la seguridad, tolerabilidad e inmunogenicidad de la candidata 25-valente (25vPnC) frente a PREVNAR 20 en lactantes sanos.

Se registraron respuestas inmunitarias sólidas frente a los 25 serotipos un mes después de la tercera dosis y un mes después de la cuarta, incluidos los cinco serotipos nuevos (15A, 23A, 23B, 24F y 35B). Las tasas de reacciones locales, acontecimientos sistémicos y efectos adversos estuvieron equilibradas entre el grupo de la candidata 25-valente y el de PREVNAR 20 en el ensayo de fase II. Los efectos adversos fueron acordes con los cuadros que suelen diagnosticarse habitualmente en este grupo de edad.

En el estudio no se identificaron efectos adversos graves relacionados con el tratamiento. La candidata a vacuna 25-valente indujo una mayor respuesta inmunitaria frente al serotipo 3 en comparación con PREVNAR 20, con concentraciones medias geométricas 8,8 veces superiores un mes después de la tercera dosis y aproximadamente 15 veces más altas un mes después de la cuarta. El fármaco incorpora una tecnología de última generación diseñada específicamente para suscitar una respuesta inmunitaria más robusta frente al serotipo 3, responsable del 10,6 % de todos los casos de enfermedad neumocócica invasiva en niños menores de cinco años en Estados Unidos. La candidata 25-valente también generó respuestas funcionales en el ensayo de actividad opsonofagocítica un mes después de la cuarta dosis para los 25 serotipos evaluados, lo que demuestra un efecto de refuerzo. Este resultado refleja el potencial de la candidata para generar anticuerpos capaces de contribuir a la eliminación funcional de la bacteria del neumococo.

En población pediátrica, la 25vPnC se está evaluando en tres estudios de fase III iniciados a principios de 2026, con hasta 6.830 participantes aleatorizados para recibir 25vPnC o PREVNAR 20. Además, Pfizer ha completado el reclutamiento de un ensayo de fase III para demostrar la consistencia de tres lotes de fabricación de 25vPnC.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Se calcula que los cinco serotipos nuevos (15A, 23A, 23B, 24F y 35B) representan en torno a un 30% adicional de los casos de enfermedad neumocócica invasiva pediátrica en Estados Unidos respecto a los cubiertos por PREVNAR 20.

Asimismo, utiliza una tecnología de última generación concebida para mejorar la respuesta frente al serotipo 3, causante del 10,6 % de los casos de enfermedad neumocócica invasiva en niños estadounidenses menores de cinco años. En adultos, Pfizer prevé incorporar al desarrollo clínico una candidata a vacuna 35-valente de quinta generación antes de que finalice 2026, a la espera del visto bueno de las autoridades reguladoras.

Fuente: Market Screener. Disponible en https://n9.cl/kfkyw

Comienza un ensayo de la vacuna contra el brote de ébola que azota RD Congo



Oct 24. El primer ensayo clínico de una vacuna contra el ébola para el brote que azota a la República Democrática del Congo (RDC) comenzó el viernes, informó el director de la Organización Mundial de la Salud.

El peor episodio de esta enfermedad en la historia del país africano ha superado los 9.700 casos, con un número de muertes mayor a 4.600.

Entre los desafíos que enfrenta la RDC está la falta de vacunas o tratamientos aprobados para la cepa de Bundibugyo, responsable de esta epidemia.

Ervebo, una vacuna aprobada para su uso contra la subespecie más común de ébola, la de Zaire, se someterá a un ensayo en humanos a gran escala en RDC para determinar si ofrece alguna protección cruzada contra la de Bundibugyo.

El ensayo comenzó con la administración de la primera dosis de Ervebo en Bunia, la capital de la provincia de Ituri y epicentro de la emergencia.

"La ciencia nos da esperanza. Hoy, en Bunia, República Democrática del Congo, se vacunó a los primeros participantes en un nuevo ensayo de vacuna contra el ébola llamado Tumaini, que significa 'esperanza' en swahili", dijo el jefe de la OMS, Tedros Adhanom Ghebreyesus, en X.

"Este ensayo nos ayudará a comprender si alguna de las vacunas candidatas diseñadas para el virus de Bundibugyo funciona", señaló.

El llamado ensayo Tumaini utilizará un enfoque de vacunación en anillo: inmunizar a los contactos que se consideran de alto riesgo de infección.

Las autoridades se preparan para incorporar además dos vacunas candidatas específicas contra el virus de Bundibugyo, actualmente en etapas tempranas de ensayos clínicos a menor escala.


Una es la de vector adenoviral ChAdOx1 desarrollada por la Universidad de Oxford y la otra, del grupo estadounidense Moderna, utiliza tecnología de ARNm.

Fuente: Yahoo! Noticias. Disponible en https://n9.cl/h24nu

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Isla de la Juventud protegerá a más de 300 niñas con la vacuna contra el virus del papiloma humano

Oct 25. Proteger la salud de una niña es también cuidar sus sueños, sus proyectos y todo el futuro que tiene por delante. Con esa mirada hacia la prevención y la vida, Isla de la Juventud (municipio especial, Cuba) se prepara para iniciar el próximo 26 de octubre una campaña de vacunación contra el virus del papiloma humano (VPH), dirigida a alrededor de 351 niñas de cuarto grado que tengan nueve años de edad.



El proceso comenzará en la escuela Josué País y se extenderá hasta el 30 de octubre, con acciones previstas también en los poblados de La Fe, Chacón y Patria.

La iniciativa forma parte de los esfuerzos del sistema de salud cubano para prevenir enfermedades asociadas a este virus y proteger desde edades tempranas la salud de las futuras mujeres.

Acerca de la importancia de esta intervención sanitaria, el doctor Víctor Doeste Hernández, responsable del Programa de Atención al Cáncer en el territorio precisó que la vacuna que se empleará en esta campaña es la Cecolin bivalente, diseñada para proteger contra los tipos 16 y 18 del virus del papiloma humano.

La Organización Mundial de la Salud (OMS) le otorgó la precalificación en octubre de 2021, tras evaluar la información disponible sobre su calidad, seguridad y eficacia.

De acuerdo con la Organización Panamericana de la Salud (OPS), los tipos 16 y 18 están relacionados con aproximadamente el 70 % de los casos de cáncer de cuello uterino en el mundo. Por eso, la vacunación constituye una herramienta fundamental para reducir el riesgo de desarrollar esta enfermedad en el futuro.

El VPH comprende un grupo de más de 200 virus. Algunos pueden provocar infecciones persistentes que, con el paso del tiempo, originan lesiones precancerosas y cáncer. Aunque la infección es frecuente, sus consecuencias pueden prevenirse en buena medida mediante la vacunación y las medidas de detección temprana recomendadas por los servicios de salud.

La aplicación de la vacuna a los nueve años responde a una razón esencial: la protección es más eficaz cuando se administra antes de que exista exposición al virus. No se trata solamente de una inyección, sino de una oportunidad para adelantarse a una enfermedad que afecta la salud y la vida de millones de mujeres.

La Cecolin no trata una infección por VPH que ya exista ni protege contra todos los tipos del virus. Sin embargo, ofrece protección frente a los tipos 16 y 18 incluidos en su formulación. La OMS reconoce la importancia de las vacunas contra el VPH como parte de las estrategias mundiales para prevenir el cáncer cervicouterino.

La jornada prevista en Isla de la Juventud representa, por tanto, un compromiso con la prevención y con el bienestar de las nuevas generaciones.


Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

El trabajo coordinado de los profesionales de la salud, las instituciones educativas y las familias será decisivo para el desarrollo de este proceso.

Porque cuidar a nuestras niñas significa mucho más que atender su salud en el presente: significa darles mejores oportunidades para crecer, aprender y construir sus sueños. Cada acción preventiva cuenta, y la vacunación contra el virus del papiloma humano es una apuesta por un futuro en el que más mujeres puedan vivir con salud y esperanza.

Fuente: VICTORIA Diario Digital de la Isla de la Juventud. Disponible en https://n9.cl/gxxl1z

WHO chief envisions AI-driven future for global health, hails Korea's vaccine equity push



Oct 26. The chief of the World Health Organization (WHO) said on Thursday that Korea is making a "substantial contribution" to global vaccine equity through its biomanufacturing training hub and pointed to AI as a tool for health care and disease surveillance.

WHO Director-General Tedros Adhanom Ghebreyesus shared his views on Korea's growing role in global health care and his meeting with President Lee Jae Myung during an interview with the Korea JoongAng Daily and JoongAng Ilbo at the Shilla Seoul in Jung District, central Seoul, on Thursday.

On Tuesday, WHO and Korea opened a new facility for WHO's global biomanufacturing training hub, designed to help transfer pharmaceutical technologies to low- and middle-income countries.

"We inaugurated a new training facility just two days ago," Tedros said. "It is a brand-new, well-equipped facility that will have the capacity to train approximately 2,000 people every year. This network will expand our training capacity and strengthen local manufacturing capabilities around the world. So Korea is already making a substantial contribution."

"Several countries expressed interest in hosting the hub, and Korea was among them," he continued. "But Korea demonstrated an especially strong commitment."

He also praised Korea's role during the Covid-19 pandemic and shared his views on how the country can contribute to WHO's pandemic preparedness initiatives.

"One of the most serious weaknesses exposed by Covid-19 was the lack of equity," he said. "Wealthy countries were able to secure vaccines very quickly. Some even obtained more doses than they needed, while poorer countries were left behind. To address this inequality, WHO proposed strengthening local production capacity, particularly in developing countries."

He noted that Korea "moved very quickly and invested substantial resources in the initiative," training approximately 4,000 people from 100 countries.

"This is a significant contribution to strengthening local production capacity," Tedros said.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

"When the next pandemic strikes, I believe the world will be better prepared, particularly in terms of equitable access to vaccines and local manufacturing capacity."

As for discussions with President Lee, Tedros said that he emphasized the role of AI in improving health care services.

"I believe that it is essential that we make the most of the opportunities offered by AI," he said. "The future of health care is digital, whether we like it or not. We now have tremendous opportunities to use digital technologies, particularly AI, to improve health care services. AI also has significant potential to strengthen health security. For example, it can be used in disease surveillance, vaccine research and development and many other areas.

"We had a very productive discussion about how these technologies could improve health systems and global health outcomes."

Tedros also said he discussed WHO's ongoing reforms with Lee.

"I briefed the president on the measures we are taking to make the organization more effective and efficient, particularly in light of the current challenges facing the world, including funding cuts," he said. "We are working to transform the organization and strengthen its ability to respond to these challenges. I believe that every crisis also presents an opportunity. The important thing is to identify the opportunities within a crisis and use them to bring about positive change. That is exactly what we are trying to do at WHO."

He also highlighted the contributions of Korean biopharmaceutical company EuBiologics, which produces oral cholera vaccines used to combat outbreaks in cholera-affected countries.

Tedros visited EuBiologics shortly before the interview.

"One of the reasons that I visited EuBiologics was to recognize the contributions that Korea's pharmaceutical industry is making to global health, particularly in the area of public health," he said. "Companies such as EuBiologics produce essential vaccines, including vaccines against cholera, typhoid fever and meningococcal disease. These diseases disproportionately affect developing countries. The challenge is that vaccines for these diseases may not generate large profit margins.

"In some cases, companies may even incur losses. That is why their commitment to public health is so important. EuBiologics is playing a valuable role in this area, and other Korean companies are also making important contributions."

He emphasized that continued investment in such products is essential to addressing unmet public health needs, particularly in developing countries.

"I was also very pleased to learn that EuBiologics has plans to develop additional public health products," he said. "That is exactly the kind of commitment we need, and I hope Korean pharmaceutical and biotechnology companies will continue to expand their contributions in this area."


On Wednesday, he also attended the World Bio Summit at Coex Magok Convention Center in Gangseo District, western Seoul, where he addressed key global health issues, including AI's transformative potential in health care systems worldwide.

Fuente: Korea JoongAng Daily. Disponible en https://n9.cl/nf8tce

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Vacuna Abdala durante el embarazo: segura, inmunogénica y con protección pasiva demostrada hasta los 24 meses en lactantes cubanos

26 oct. Un estudio observacional de cohorte prospectivo, realizado en el Hospital Universitario Ginecobstétrico "Ramón González Coro" (La Habana) publicado en la Revista Cubana de Obstetricia y Ginecología, confirma que la vacuna cubana Abdala (CIGB 66), administrada durante el embarazo o en la etapa preconcepcional, es segura y confiere inmunidad pasiva funcional a los lactantes.



La investigación, liderada por el Hospital "Ramón González Coro" y el Centro de Ingeniería Genética y Biotecnología (CIGB), evaluó a 34 díadas madre-lactante con seguimiento de 24 meses y muestras de sangre pareadas.

Los resultados mostraron que el 100 % de los recién nacidos presentó IgG anti-RBD detectable en sangre de cordón (media geométrica de 1288,5 BAU/ml), lo que evidencia una transferencia placentaria eficiente. A los dos años, los títulos disminuyeron un 79,6 % y la capacidad neutralizante un 70,6 %, hallazgos consistentes con la naturaleza transitoria de la inmunidad pasiva.

El estudio no identificó eventos adversos graves atribuibles a la vacunación materna. La frecuencia de eventos adversos maternos fue baja (15,3 %), todos leves y sin relación causal tras aplicar los criterios de Bradford Hill.

En los lactantes, las morbilidades observadas correspondieron a patologías pediátricas comunes, sin señales de seguridad atribuibles a la exposición *in utero*.

Este trabajo llena una brecha crítica de evidencia: hasta ahora, los datos a largo plazo sobre inmunidad pasiva en lactantes nacidos de madres vacunadas con vacunas de subunidad proteica contra la COVID-19 eran escasos.

Los hallazgos refuerzan la seguridad de la vacunación materna como estrategia de protección temprana y subrayan la necesidad de la inmunización directa en la infancia, dado el declive de anticuerpos a los dos años.


Asimismo, identifican factores modificadores relevantes: la obesidad materna se correlacionó inversamente con los títulos de IgG al parto ($\rho = 0{,}323$; $p = 0{,}048$), y los lactantes pretérmino mostraron una mayor frecuencia de infección por SARS-CoV-2 (50 % frente a 6,1 %), lo que sugiere una vulnerabilidad inmunológica más allá de los títulos de anticuerpos.

Vea el artículo completo:
Aguilar Estrada JA, Campa Legrá I, Reyes Pelier Y, Mendoza Quiñones R, Muzio-González VL, Baladrón Castrillo I, et al. Seguridad e inmunidad humoral a 24 meses en lactantes tras vacunación materna con Abdala contra COVID-19. Rev Cubana Obstet Ginecol. 2026;52:e889.

Fuente: Infomed Temas de Salud. Disponible en https://n9.cl/t56966

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

NEC contributes to AI powered vaccine design through the EU funded PREPAIR VAC pandemic preparedness project



Oct 27. NEC Corporation today announced its participation in PREPAIR VAC, a Horizon Europe–funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design. The grant has been awarded to NEC OncoImmunity AS (NOI) – a wholly owned subsidiary of NEC Bio within NEC Corporation – alongside several European partners comprising a research consortium.

This four-year research grant beginning in September 2026, with a total budget of approximately €6.5 M, aims to address major challenges in vaccine design in the context of pandemic preparedness, bringing together leading organizations across the vaccine development ecosystem. European partners from academia, industry, and public health have come together to establish a next-generation vaccine development framework capable of responding more rapidly to emerging infectious diseases.

Within the consortium, NOI, the primary initiator of the project, is responsible for AI-powered antigen prediction and vaccine design, applying its cutting edge and advanced technologies to anticipate viral evolution and design broadly protective antigens. This approach is intended to support the development of broadly protective vaccine candidates and reduce the time required to progress from pathogen identification to vaccine design.

> *"PREPAIR VAC reflects the European Commission's confidence in the role of AI-driven design in strengthening European pandemic preparedness. Building on our experience in the field, NEC is applying AI technologies to create novel rapidly scalable vaccines that address current pathogen and host diversity while anticipating future mutations. The consortium brings together complementary expertise across the vaccine development lifecycle to generate a solid proof-of-concept package using preclinical and translational models."*
>
> *Dr. Kaidre Bendjama, Chief Scientific Officer, NEC OncoImmunity AS*

The project is coordinated by the European Vaccine Initiative (EVI) and includes partners specializing in manufacturing, formulation, preclinical validation, and ethical, legal, regulatory and societal aspects of vaccine innovation. In addition to scientific and technological development, PREPAIR VAC also addresses responsible use of AI, public trust, and regulatory considerations.

Fuente: News Medical Life Sciences. Disponible en https://n9.cl/sci1q

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Vietnam ya cuenta con su primera vacuna antigripal en aerosol nasal, siendo el VNVC el primero y único en implementarla

28 oct. En la mañana del 28 de octubre, el Sistema de Vacunación VNVC lanzó oficialmente la nueva vacuna antigripal en aerosol nasal de AstraZeneca (Reino Unido). Mediante un método de pulverización que rocía la vacuna directamente en la mucosa nasal, ofrece una experiencia de vacunación suave y cómoda, especialmente adecuada para niños con miedo a las agujas.

"Por primera vez en Vietnam, los niños de entre 2 y 18 años cuentan con una opción adicional para la prevención de la gripe gracias a una vacuna de nueva tecnología en forma de aerosol nasal, que no requiere agujas y estimula la inmunidad de triple acción. El Centro Nacional de Inmunización de Vietnam (VNVC, por sus siglas en inglés) es la primera y única unidad seleccionada por AstraZeneca para distribuir esta vacuna en Vietnam."

El Sr. Atul Tandon, Presidente y Director Ejecutivo de AstraZeneca Vietnam, junto con representantes del Sistema de Vacunación VNVC, en la ceremonia de lanzamiento de la nueva vacuna antigripal en aerosol nasal el 28 de octubre. Foto: Nhan Le

La Dra. Bach Thi Chinh, Directora Médica del Sistema de Vacunación VNVC, afirmó que se trata de una vacuna antigripal en aerosol nasal de nueva tecnología, con más de 20 años de seguimiento de seguridad a nivel mundial . Hasta la fecha, la vacuna se ha implementado en más de 34 países y territorios, con más de 200 millones de dosis distribuidas globalmente.

La vacuna antigripal inhalada es una vacuna de virus vivos atenuados que protege contra tres cepas del virus de la influenza: A/H1N1, A/H3N2 y B/Victoria. Los niños de 2 a 9 años que nunca han sido vacunados contra la influenza necesitan dos dosis, con un intervalo mínimo de cuatro semanas; los niños que ya han sido vacunados pueden recibir una sola dosis, según su historial de vacunación. Los niños de 9 a 18 años necesitan una sola dosis. La vacuna debe administrarse anualmente para mantener la protección contra el virus de la influenza, que está en constante evolución.

Este tipo de vacuna se diferencia no solo por su método de administración sin agujas, sino también por estimular una respuesta inmunitaria de "tres niveles", que incluye la inmunidad de las mucosas en la nariz y la garganta, que ayuda a proteger contra la entrada del virus de la gripe; la inmunidad sistémica, que crea anticuerpos contra el virus; y la inmunidad celular, que ayuda a identificar y eliminar las células infectadas por el virus.



Según los datos de las investigaciones, la vacuna ha demostrado una eficacia de hasta el 88 % en la prevención de la gripe contra cepas virales similares a las incluidas en la vacuna. La vacuna antigripal en formato de aerosol ofrece una opción adicional de prevención para niños, junto con la vacuna inyectable, afirmó la Dra. Bach Thi Chinh.

Las vacunas antigripales inhaladas requieren un almacenamiento en ultracongelación riguroso y una cadena de frío eficiente. Gracias a un sistema de almacenamiento en frío estandarizado internacionalmente,

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS









que incluye ultracongelación, y a sus capacidades profesionales de transporte y suministro, VNVC tiene la ventaja de haber sido elegida por AstraZeneca para ser pionera en la implementación de esta nueva tecnología de vacuna antigripal en Vietnam.

El Sr. Atul Tandon, Presidente y Director Ejecutivo de AstraZeneca Vietnam, comentó: “En AstraZeneca, creemos que la prevención de enfermedades es la base de un sistema de salud sostenible. Mediante nuestra colaboración con VNVC, buscamos facilitar el acceso de las personas a soluciones preventivas adecuadas, al tiempo que promovemos el diálogo científico y creamos conciencia sobre el papel de la vacunación en la protección de la salud pública”.

Tan pronto como el VNVC lanzó la vacuna antigripal en aerosol nasal, muchos padres llevaron a sus hijos a los centros de vacunación para recibir asesoramiento y utilizar el nuevo método de vacunación.

La Sra. Nguyen Thi Nhu Ngoc (35 años, del barrio de Tan Son), que llevó a su hijo de 7 años al centro de vacunación VNVC Hoang Van Thu (Ciudad Ho Chi Minh), comentó que su hijo siempre se ponía nervioso durante las vacunaciones, por lo que tenía que animarlo mucho. A veces se mostraba poco cooperativo, lo que hacía que el proceso de vacunación durara más. Cuando se enteró de la vacuna que solo requiere un aerosol nasal, vacunó a su hijo de inmediato.

"Hay muchos casos de gripe en la escuela de mi hijo, y se propaga muy rápido, así que quiero tomar precauciones con anticipación. Antes, cuando llegaba el momento de las vacunas, tanto mi hijo como yo nos preparábamos mentalmente, pero ahora con la nueva vacuna, me resulta mucho más fácil prevenir la enfermedad", compartió la Sra. Ngoc.

Primer plano del uso de la nueva tecnología de la vacuna contra la gripe, que consiste en un suave y práctico "aerosol en niebla". Foto: Nhan Le

El Sr. Minh Trung (35 años) también llevó a sus dos hijos, de 10 y 15 años, al centro de vacunación VNVC para que se vacunaran contra la gripe. Comentó que cada vez que se vacunan, la familia suele prepararse mentalmente, sobre todo cuando uno de los niños le tiene miedo a las inyecciones, lo que preocupa al otro. "El médico les indicó a los niños que respiraran con normalidad mientras les

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

administraban el aerosol, así que el proceso fue mucho más tranquilo y cómodo", compartió el Sr. Trung.

En muchas localidades, los casos de gripe y enfermedades respiratorias están aumentando. Según el Centro para el Control de Enfermedades de Ciudad Ho Chi Minh (HCDC), en una semana a mediados de octubre, la ciudad registró 34.664 casos de infecciones respiratorias agudas, lo que supone un incremento de más del 64% con respecto al promedio de las cuatro semanas anteriores. De las muestras que dieron positivo para gripe, el virus A/H1N1 representó casi el 77%.

Según el Dr. Truong Huu Khanh, vicepresidente de la Asociación de Enfermedades Infecciosas de Ciudad Ho Chi Minh, la gripe estacional no es una enfermedad respiratoria común y puede causar complicaciones graves, incluso en niños sanos. Además de neumonía e insuficiencia respiratoria, la gripe puede provocar encefalitis, alteración de la conciencia, coma, miocarditis o sobreinfección bacteriana que puede derivar en sepsis, shock, fallo multiorgánico y la muerte.

Los niños también pueden transmitir el virus a sus familiares, especialmente a los ancianos y a quienes padecen enfermedades preexistentes. El Dr. Khanh señaló que la vacuna antigripal en aerosol nasal es una opción adicional para la prevención anual de la gripe en niños, sobre todo en aquellos que le tienen miedo a las agujas.

Anteriormente, VNVC fue pionera en la introducción de casi 25 vacunas y productos biológicos nuevos de última generación en Vietnam, como vacunas contra la enfermedad de manos, pies y boca, el dengue, la enfermedad neumocócica, la enfermedad meningocócica, el herpes zóster y el virus sincitial respiratorio (VSR).

Fuente: VIETNAM.VN. Disponible en https://n9.cl/dqh3j

Making mRNA in Latin America: Brazil's new vaccine platform heads into human trials

Oct 29. Brazil has produced vaccines for 50 years, but when the COVID-19 pandemic hit, it couldn't make mRNA vaccines of its own. Now Brazil's Fiocruz Bio-Manguinhos vaccine institute is about to change that, with the first Brazilian patented mRNA vaccine platform starting human trials in 2027.



RNA product development at Bio-Manguinhos
Photo: André Rocha

CEPI spoke to Dr Patrícia Neves, who is leading the CEPI-supported project, about what that means for Brazil and Latin America, as well as for other countries and regions hoping to learn from it.

When Patrícia Neves thinks back to the COVID pandemic, her memory is of an initial sense of helplessness.

Her country, Brazil, has a proud history of making vaccines – shots that have protected its people from diseases such as polio and meningitis for five decades since Fiocruz Bio-Manguinhos was founded in 1976 as part of a government commitment to public production. But when COVID-19 hit, Brazil's manufacturing capabilities were not enough.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Without the development expertise to make its own new vaccines, the government had, like others, to wait for technology transfer to make the Oxford-AstraZeneca COVID vaccine and to rely on outside sources for the delivery of mRNA vaccines.

“We had to negotiate,” said Neves, who is now head of RNA product development at Bio-Manguinhos. “Even though we had great manufacturing capacity, we weren’t able to develop our own vaccines. We had to find someone to transfer the vaccine technology to us.”

Brazil’s goal since then has been to create and expand the scientific and manufacturing capabilities to design, develop and produce vaccines in one place – at home. And at the Bio-Manguinhos vaccine facility in Rio de Janeiro, that ambition is now being realised as part of a partnership with CEPI.

When it began, Nevez says, the team’s work was at the earliest stages – enough to show their mRNA idea was feasible but not enough to develop vaccines that could be trialed in people. The challenge was to show that Fiocruz Bio-Manguinhos could make an mRNA vaccine reliably, at pilot scale, in its own laboratories.

Neves says the team chose COVID-19 for its first mRNA vaccine candidate for practical reasons. COVID vaccination is part of Brazil’s national immunisation programme and is given every year to people in risk groups, so there is a ready-made need for it.

And the results are already encouraging. The development team has now produced more than seven batches of its mRNA COVID vaccine candidate and in August 2026, Brazil’s regulator gave permission for it to be tested in a Phase 1 human trial. The hope is that the first volunteers in the trial will be vaccinated in early 2027.

“Fiocruz brings decades of manufacturing experience and, now, a rapid-response mRNA vaccine platform it can adapt to new threats,” said Ian Hart, CEPI’s vaccine manufacturing lead. “That’s what our 100 Days Mission work is focused on: the ability to develop and produce vaccines rapidly across all regions, north and south, and closer to where outbreaks can start.”

For Neves and her colleagues, their “home-grown” mRNA COVID vaccine is the start of what they hope will be a much larger project. The mRNA vaccine platform can be adapted to new targets, and Fiocruz scientists are already testing it in a tuberculosis vaccine candidate.

They are also working on an mRNA vaccine against leishmaniasis, a parasitic skin disease that affects people in countries across Latin America and Africa, and have early proof of concept for others, including yellow fever and RSV.

It’s this adaptability that will matter most when the next pandemic threat emerges. When COVID-19 hit, Brazil had the factories but not the science to design new vaccines. “Now we’ll have the development capacity together with the production capacity,” Neves said. “That makes a lot of difference in the event of pandemics.”

The plan is for the impact to also reach far beyond Brazil. Because Fiocruz is a government-backed organisation its interests are not just market driven, but also guided by cooperation and equity, Neves said, meaning its scientists are now eager to “share our knowledge with others”.

Fiocruz has already hosted researchers from other countries in Latin America, with more visits planned soon. Neves is also involved in efforts to bring African colleagues to Brazil. Her aim is to involve them earlier than technology transfer usually does. “We’d like to bring them to work with us from the beginning of the development,” she says.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

While she knows it won't be immediate, Neves is optimistic about how this expertise-sharing will help other countries in the global south to strengthen their own and the world's health security. "We'll need some time to see the impact," she says, "but I think it will be a huge impact.

Fuente: CEPI. Disponible en https://n9.cl/lcsqu9

Biod, CTCBIO Team Up to Commercialize 'Next-Generation Vaccines,' Targeting a Market That Has Grown Tenfold

Oct 30. Animal-health biotech startup Biod has joined forces with veterinary pharmaceutical company CTCBIO to commercialize next-generation viral vector vaccines and expand into global markets. The companies are targeting the global HVT vector vaccine market, which has grown roughly tenfold in the past five years, with the goal of demonstrating the competitiveness of a homegrown vaccine platform.

Technology transfer of two next-generation multivalent vaccines builds industry-academia-research collaboration

Biod and CTCBIO said on the 30th that they signed a technology transfer agreement on the 28th at CTCBIO's headquarters in Seoul covering two recombinant HVT vector vaccines to prevent low-pathogenic avian influenza (AI).

The Jeonbuk National University Center for Avian Disease also took part in the event, signing a three-party memorandum of understanding (MOU) to industrialize the HVT vector vaccine platform. The parties agreed to establish a close collaboration framework spanning vaccine research and development, product development, contract manufacturing (CMO) and expansion into overseas markets.

The vaccines covered by the technology transfer are rHVT-Y280, which is designed to prevent recently emerging variants of low-pathogenic avian influenza, and rHVT-Y280-G2d, a multivalent vaccine designed to also protect against variant infectious bursal disease (IBD).

HVT vector vaccine platform draws global market attention

HVT (Herpesvirus of Turkey) vector vaccines are a next-generation vaccine platform that uses turkey herpesvirus as a gene-delivery vehicle. Their high genetic stability and efficient antigen delivery enable them to induce both humoral immunity and a strong cellular immune response.

A single dose on the first day of life can provide lifelong immunity. The vaccines can also be administered in ovo, enabling automated mass vaccination at hatcheries—a capability that has drawn considerable attention in the global poultry vaccine market.

Under the agreement, Biod will provide its proprietary HVT vector vaccine platform technology, while CTCBIO plans to use the KVGMP manufacturing facilities of its subsidiary, CTCVAC, to establish a mass-production system and move ahead with commercializing the products.

"Combining production capabilities to become a global leader"

The global HVT vector vaccine market has high barriers to entry, with only a handful of multinational pharmaceutical companies, including Boehringer Ingelheim and MSD, possessing the technology. At the same time, the field is considered to have significant growth potential.

"The global HVT vector vaccine market has been on a steep upward trajectory, growing roughly tenfold in the past five years," said Kang Min, CEO of Biod. "We will combine Biod's next-generation viral vector vaccine platform technology with the strong manufacturing and commercialization

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

capabilities of a domestic pharmaceutical company to develop products that can compete in global markets."

CTCBIO CEO Cho Chang-seon also said, "We believe that securing the latest technologies ahead of the competition and gaining an early foothold in the market are of utmost importance. Building on our latest KVGMP manufacturing facilities, we will establish a mass-production system for HVT vector vaccines and work closely with Biod to lead the global market."

Biod is a promising tech startup developing third-generation genetic vaccines and immuno-oncology drugs based on a range of herpesvirus vector platforms. Building on its collaboration with CTCBIO, the company is expected to expand the industrialization of its R&D results and strengthen its position in the global animal vaccine market.

Fuente: KOREA STARTUP POST. Disponible en https://n9.cl/qfxr7

La OPS lanza un fondo unificado para abaratar vacunas y medicamentos en la región

30 oct. Organización Panamericana de la Salud lanzó su nuevo mecanismo de compras conjuntas y pasó de la teoría a la práctica en semanas.

El Fondo Rotatorio Regional, aprobado en octubre por el 63.º Consejo Directivo de la OPS, ya financiaba la compra de millones de dosis contra el sarampión para frenar el brote más grave que enfrenta Guatemala en años.

El respaldo llegó también desde otros puntos de la región. República Dominicana confirmó ante el organismo su apoyo a la unificación, mientras Estados Unidos mantenía congelado el pago de sus cuotas y México asumía la conducción política del comité ejecutivo de la OPS.

"El nuevo mecanismo fusiona dos fondos previos y permite a 33 países y nueve territorios de América Latina y el Caribe acceder a insumos sanitarios a precios hasta un 50% menores que los de países con ingresos similares."

Qué cambia con el nuevo Fondo Rotatorio Regional

El 63.º Consejo Directivo de la OPS, reunido en Washington entre el 28 de septiembre y el 2 de octubre, aprobó fusionar el histórico Fondo Rotatorio para el Acceso a Vacunas con el Fondo Estratégico en un único mecanismo.

La nueva estructura concentra vacunas, medicamentos, diagnósticos y equipamiento médico bajo un mismo esquema de compra conjunta. Durante el último bienio, ambos fondos ayudaron a proteger a unas 170 millones de personas, según datos oficiales de la OPS.



El nuevo fondo permite que 33 países y nueve territorios de América Latina y el Caribe adquieran insumos a precios más bajos que si negociaran de forma individual.

Santiago Cornejo, gerente ejecutivo de los Fondos Rotatorios de la OPS/OMS, explicó a

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

través de una nota de prensa, que la compra a escala permite pagar más de un 50% menos que otros países de ingresos similares.

“Nosotros como OPS gerenciamos los fondos, pero los fondos son de los países. Los países los crearon y definen sus prioridades”, señaló Cornejo durante el 1.er Congreso Iberoamericano de Salud FICS, realizado el 14 y 15 de octubre en Buenos Aires, Argentina.

Producción regional y medicamentos de alto costo

En 2020, apenas el 1.5% del volumen de vacunas comprado mediante los fondos provenía de fabricantes regionales. Según el informe anual de la OPS correspondiente al período julio de 2025-junio de 2026, esa proporción trepó a cerca de un 26% durante 2025.

El organismo también firmó un acuerdo para reservar dosis ante una eventual influenza pandémica y otro de transferencia tecnológica para fabricar vacunas antigripales estacionales con plataformas celulares en la propia región.

En medicamentos de alto costo, la OPS informó reducciones de entre 60% y 90% en tratamientos para cáncer de próstata y mama, esclerosis múltiple y cáncer pediátrico.

Para sostener esas compras en países con restricciones financieras, la OPS y el Banco Interamericano de Desarrollo (BID) diseñaron un esquema de garantías por hasta USD 1,000 millones, que podría generar ahorros de entre USD 850 millones y USD 2,200 millones en 24 países.

La inteligencia artificial pasa de piloto a sistema

Sebastián García Saisó, director del Departamento de Evidencia e Inteligencia para la Acción en Salud de la OPS, sostuvo que la tecnología ya ofrece resultados concretos en tareas puntuales. “La inteligencia artificial en salud ya no es una promesa. La pregunta es cómo lograr que produzca valor real para las personas”, afirmó durante el congreso porteño.

La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) autorizó más de 1,600 dispositivos con inteligencia artificial, 258 de ellos solo en 2025.

García Saisó citó el ensayo MASAI, realizado en Suecia con cerca de 100.000 mujeres, donde la mamografía asistida por IA detectó el 81% de los cánceres frente al 74% de la lectura convencional.

Según el especialista, muchos proyectos fracasan al escalarlos por fragmentación de datos y falta de interoperabilidad, no por fallas de los algoritmos. Su propuesta: “Datos primero, inteligencia artificial después, ciberseguridad siempre”.

Guatemala combate con el fondo el peor brote de sarampión de la región

El caso guatemalteco ilustra para qué sirve en la práctica el nuevo mecanismo. Un informe de situación de la OPS detalló que la región acumulaba 55,792 casos de sarampión y 77 muertes, con una caída del 35% en dos semanas pero con las primeras muertes del año registradas en Estados Unidos y Perú.

A través del Fondo Rotatorio, la OPS apoyó la compra de 3 millones de dosis de vacuna contra sarampión y rubéola y de 1.74 millones de dosis de la triple viral, destinadas en gran parte a Guatemala.

El país mantiene una campaña de vacunación activa en los departamentos de Quiché, Chiquimula, Sololá e Izabal y solicitó 500.000 dosis adicionales.

Guatemala y México registran un número reproductivo del virus por debajo de uno, mientras que en Estados Unidos ese indicador se ubica en 1.4, según el mismo informe de la OPS.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

La diputada mexicana Mónica Magaña, que participó del Consejo Directivo en Washington, propuso ante los ministros de la región una hoja de ruta jurídica para facilitar compras consolidadas internacionales y el uso de líneas de crédito, según consignó el portal politico.mx.

República Dominicana amplía su esquema nacional de vacunación

República Dominicana reafirmó ante el Consejo Directivo de la OPS su respaldo a la armonización de los Fondos Rotatorios Regionales, mecanismo que el país utiliza para acceder a vacunas, medicamentos esenciales y tecnologías sanitarias, según difundió Diariosalud.do, portal dominicano de salud.

La OPS también contribuyó al fortalecimiento de las capacidades nacionales en planificación, vigilancia epidemiológica y preparación ante emergencias sanitarias del país caribeño, de acuerdo con ese medio.

El respaldo dominicano no es nuevo. Durante un acto por el Día Mundial contra la Neumonía, el ministro de Salud, Víctor Atallah, destacó los avances del Programa Ampliado de Inmunizaciones y la incorporación de la vacuna neumocócica 20-valente al esquema nacional, de acuerdo con *Diario Libre*, diario dominicano.

En esa misma actividad, la directora de Inmunoprevenibles por Vacunas del país, Aida Lucía Vargas, precisó ante el diario: “Las vacunas se adquieren a través del Fondo Rotatorio de la OPS y la OMS, y su impacto justifica cada esfuerzo”.

Un representante de la OPS citado por la publicación añadió que el país cuenta hoy con un esquema de vacunación que incluye la PCV20 y la vacuna contra la influenza.

Fuente: infobae. Disponible en https://n9.cl/24rzj

Russia’s Health Ministry registers second vaccine against meningococcal group B



Oct 30. Russia’s Health Ministry has registered Pfizer’s recombinant vaccine Trumenba against serogroup B meningococcal disease. It has become the second vaccine of this kind registered in the country, after GSK’s Bexsero.

Trumenba is intended for the immunisation of people aged 10 and over. The vaccine contains two recombinant protein antigens from serogroup B meningococcus. Two primary vaccination schedules are available: a two-dose schedule with a six-month interval, or a three-dose schedule.

Serogroup B meningococcus can cause severe infections, including meningitis and sepsis. However, the age indications for the two vaccines differ: unlike Trumenba, Bexsero can be used from two months of age.

Earlier, GxP News reported the Russian registration of another Pfizer meningococcal vaccine, Nimenrix. It is intended for the prevention of infections caused by serogroups A, C, W-135 and Y. The drug received its registration certificate in March 2026.

Fuente: GxP News. Disponible en https://n9.cl/pyxqeo

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/10/23"[Date - Publication] : "2026/10/31"[Date - Publication])) 283 records

Vaccines for Cancer: A Translational Science Review.

Disis ML, Chun BMN, Dhillon KK, Liao JB, Hunter N, Cecil DL. JAMA. 2026 Oct 27;336(16):1454-1462. doi: 10.1001/jama.2026.15540. PMID: 42766303 Review.

Measles: "Stagnant" vaccine coverage has led to global resurgence, analysis finds.
Furneaux R. BMJ. 2026 Oct 23;395:e101230. doi: 10.1136/bmj-2026-101230. PMID: 42919485 No abstract available.

Moderna mRNA vaccine almost halves the risk of skin cancer returning.
Basu M. Nature. 2026 Oct 23. doi: 10.1038/d41586-026-03417-0. Online ahead of print. PMID: 42919957 No abstract available.

New vaccine research aims to protect poultry from highly contagious bird flu.
Carossino M, Sarr S. Am J Vet Res. 2026 Oct 23:1. doi: 10.2460/ajvr.26.08.0359. Online ahead of print. PMID: 42915495 Free article. No abstract available.

Safety of Live Vaccine Administration in Patients with Inflammatory Bowel Disease on Immune-Modifying Therapy.
Caldera F, Hayney MS, Zhang X, Kappelman MD, Brenner EJ. Am J Gastroenterol. 2026 Oct 27. doi: 10.14309/ajg.0000000000004238. Online ahead of print. PMID: 42937531 No abstract available.

Integrating life-course immunization within harm-reduction outreach for key populations in India: Operationalizing the YUVA framework.
Bhatt LK. Vaccine. 2026 Oct 24;92:129112. doi: 10.1016/j.vaccine.2026.129112. Epub 2026 Sep 4. PMID: 42696824 No abstract available.

Minimal potency loss of reconstituted yellow fever vaccine over six hours: implications for fractional-dose vaccination.
Nammunige NA, Mills DJ, Hugo LE, Furuya-Kanamori L. J Travel Med. 2026 Oct 30;33(7):taag069. doi: 10.1093/jtm/taag069. PMID: 42490404 No abstract available.

A commentary on "Effect of varicella vaccine introduction on chickenpox incidence in Kingdom of Bahrain".
Choi UY. Clin Exp Pediatr. 2026 Oct 29. doi: 10.3345/cep.2026.03202. Online ahead of print. PMID: 42952440 Free article. No abstract available.

A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes.
Pardo-Seco J, Rodriguez-Tenreiro-Sánchez C, Giné-Vázquez I, Mallah N, Mirás-Carballal S, Piñeiro-Sotelo M, Cribeiro González M, Conde Pájaro M, González-Pérez JM, Rivero-Calle I, Bello X, Razzini JL, Salas A, Harris RC, Loiacono MM, van Aalst R, Farre M, Dufournet M, Dyrby Johansen N, Modin D, Biering-Sørensen

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

T, Duran-Parrondo C, Martinón-Torres F; GALFLU Trial Team. Clin Infect Dis. 2026 Oct 28;83(4):e887-e891. doi: 10.1093/cid/ciag466. PMID: 42546169 Free PMC article. Clinical Trial.

Influenza Vaccine Effectiveness Across Nutritional Status Categories in Patients Hospitalized With Acute Heart Failure: A Secondary Analysis of the PANDA II Trial.
Liu X, Wang Z, Hua C, Wu Y, Tang Y, Xiong Y, Liu J, Zhang J, Jiang C, Dong J, Du X. Circ Heart Fail. 2026 Oct 27:e014659. doi: 10.1161/CIRCHEARTFAILURE.126.014659. Online ahead of print. PMID: 42935449 No abstract available.

Early herpes zoster after the first dose of recombinant zoster vaccine in allogeneic haematopoietic cell transplant recipients: a self-controlled case series analysis.
Chung Y, Kim EJ, Kwag D, Cho SY, Lee DG, Lee R. Clin Microbiol Infect. 2026 Oct 27:S1198-743X(26)00593-8. doi: 10.1016/j.cmi.2026.10.016. Online ahead of print. PMID: 42946162 No abstract available.

Correction to: A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017.
[No authors listed] Clin Infect Dis. 2026 Oct 28;83(4):e920. doi: 10.1093/cid/ciag318. PMID: 42507480 Free PMC article. No abstract available.

Immunogenicity of CpG-Adjuvanted Hepatitis B Vaccine in Hematopoietic Cell Transplant Recipients.
Einarsdottir S, Yan J, Goldstein I, Usiak S, Palazzo M, Ponce DM, Perales MA, Shah GL, Kamboj M. Blood Adv. 2026 Oct 30:bloodadvances.2026021625. doi: 10.1182/bloodadvances.2026021625. Online ahead of print. PMID: 42962267 No abstract available.

Societies Release Vaccine Recommendations for Respiratory Virus Season.
Anderer S. JAMA. 2026 Oct 27;336(16):1399. doi: 10.1001/jama.2026.20006. PMID: 42826041 No abstract available.

First mRNA Cancer Vaccine Succeeds in Phase III Trial.
[No authors listed] Cancer Discov. 2026 Oct 26:OF1. doi: 10.1158/2159-8290.CD-NW2026-0098. Online ahead of print. PMID: 42929716

Expanding Epstein-Barr virus-associated disease burden prioritises vaccine development.
Xie C, He YQ, Zeng MS, Sun C. Lancet Microbe. 2026 Oct 28:101577. doi: 10.1016/j.lanmic.2026.101577. Online ahead of print. PMID: 42950864 Free article. No abstract available.

Reply to 'Comment on "Effectiveness of respiratory syncytial virus vaccination in solid organ transplant recipients in the United States'.
Hasan L, Yetmar ZA. Am J Transplant. 2026 Oct 30:S1600-6135(26)02858-3. doi: 10.1016/j.ajt.2026.10.023. Online ahead of print. PMID: 42962762 No abstract available.

Author Correction: Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Liu Y, Wang Z, Zhuang X, Zhang S, Chen Z, Zou Y, Sheng J, Li T, Tai W, Yu J, Wang Y, Zhang Z, Chen Y, Tong L, Yu X, Wu L, Chen D, Zhang R, Jin N, Shen W, Zhao J, Tian M, Wang X, Cheng G. Nat Commun. 2026 Oct 30;17(1):11289. doi: 10.1038/s41467-026-79108-1. PMID: 42963378 Free PMC article. No abstract available.

Investments in seasonal influenza vaccination programs pack a punch for pandemic preparedness.
Shen AK, Tupps C, Bino S, Chipoya M, Jabidze L, Janashia A, Joksimovic M, Jovanovic V, Maswadi N, Musa S, Otorbaeva D, Stavridis K, Tengbriacheu C, Tzekov V, Teneva BV, Zahra D, Zangmo C, Akmatova R, Edwards A, Meslé MMI, Tempia S, Bresee JS. Vaccine. 2026 Oct 24;92:129098. doi: 10.1016/j.vaccine.2026.129098. Epub 2026 Sep 3. PMID: 42691820 Free article.

T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges.
Shao Y, Xie Z, Wang R. Vaccine. 2026 Oct 24;92:128992. doi: 10.1016/j.vaccine.2026.128992. Epub 2026 Sep 11. PMID: 42727399 Review.

The risk of idiopathic thrombocytopenic purpura after first and second measles, mumps, rubella (MMR) vaccine doses in children born in England 2000-2019.
Andrews N, Stowe J, Hani E, Jeffery-Smith A, Ramsay M. Vaccine. 2026 Oct 24;92:129168. doi: 10.1016/j.vaccine.2026.129168. Epub 2026 Sep 22. PMID: 42771940 Free article.

Vaccine mis- and disinformation and the illusion of autonomy.
Pahlman K, Silva DS. Vaccine. 2026 Oct 24;92:129103. doi: 10.1016/j.vaccine.2026.129103. Epub 2026 Sep 8. PMID: 42710150 No abstract available.

Proportion of Colonized Person-time With Streptococcus pneumoniae and Duration of Colonization With Individual Serotypes in Young Peruvian Children.
Howard LM, Huang X, Edwards KM, Zhu Y, Griffin MR, Vidal JE, Klugman KP, Gil AI, Soper NR, Thomsen IP, Gould K, Hinds J, Lanata CF, Grijalva CG. Pediatr Infect Dis J. 2026 Oct 23. doi: 10.1097/INF.0000000000005456. Online ahead of print. PMID: 42919463

Designing a tumor landscape-modifying vaccine with a unique TLR2/6 agonist for refractory pancreatic cancer.
Cho S, Kim HY, Kim N, Park J, Kim S, Song EC, Lee HS, Kim U, Ban H, Hwang S, Mun J, Kwon E, Do Y, Kim HE, Suh JH, Kim SB, Yoon I, Kong J, Kang M, Min DS, Kim S. Cell Mol Immunol. 2026 Oct 27. doi: 10.1038/s41423-026-01480-1. Online ahead of print. PMID: 42946799

mRNA encoding norovirus VP1 produces antigenically functional virus-like particles in vitro.
Reyes Ballista JM, David C, Pirrone A, Gonzalez-Fernandez E, Wei J, Wen Z. Vaccine. 2026 Oct 26;95:129272. doi: 10.1016/j.vaccine.2026.129272. Online ahead of print. PMID: 42933242 Free article.

Correction: Japanese-Language AI Agent System for Human Papillomavirus Vaccine Infoveillance and Public Communication: Development and Feasibility Evaluation.
Liu J, Yang S, Ma D, Niu Q, Zhang Z, Nagai-Tanima M, Aoyama T. JMIR Infodemiology. 2026 Oct 28;6:e109982. doi: 10.2196/109982. PMID: 42950346 Free PMC article. No abstract available.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Safety and immunogenicity of mRNA-1345 revaccination at least 12 months following primary vaccination with a licensed protein subunit RSV vaccine.
Desai M, Cardona J, Khetan S, Mehta S, Kapoor A, Okparavero A, Lin Z, Priddy F. Vaccine. 2026 Oct 24;92:129068. doi: 10.1016/j.vaccine.2026.129068. Epub 2026 Sep 8. PMID: 42710149 Free article. Clinical Trial.

Toward a Brighter Future in Vaccine Safety Science: A Call For Investments, Capitalizing on Scientific Opportunities and A National Vaccine Safety Board.
Salmon DA, Buttery J, Carleton B, Black S. J Infect Dis. 2026 Oct 30:jiag535. doi: 10.1093/infdis/jiag535. Online ahead of print. PMID: 42961923 No abstract available.

Enhancing mRNA-lipid nanoparticle vaccine-induced T cell responses by simple supplementation with class B CpG oligodeoxynucleotides.
Hirata H, Abe Y, Itoh Y, Hirai T, Yoshioka Y. Int J Pharm. 2026 Oct 26;706:127604. doi: 10.1016/j.ijpharm.2026.127604. Online ahead of print. PMID: 42933514 Free article.

Corrigendum to "HIV-Gag VLP-based vaccine purification at manufacturing scale: Combination of counterflow centrifugation and nuclease treatment as a key to DNA depletion" [New Biotechnol. 93 (2026) 264-279/ISSN 1871-6784].
von Elling-Tammen M, Machava M, Möhle JK, Nunna S, Bizos A, Tomala M, Krumbein F, Thom V, Stitz J, Barbe S, Krause A. N Biotechnol. 2026 Oct 30;97:13. doi: 10.1016/j.nbt.2026.10.012. Online ahead of print. PMID: 42962629 Free article. No abstract available.

Innovative vaccine strategies for sustainable control and eradication of peste des petits ruminants virus.
Bello MB, Hameed SA, Abdullahi AM, Lawal N, Aliyu RM, Alkali BR, Tambuwal FM, Jibril AH, Abubakar MB, Ibrahim AM, Shehu Z, Daneji AI. Anim Health Res Rev. 2026 Oct 26;27:e7. doi: 10.1017/S1466252326100164. PMID: 42929676 Review. No abstract available.

Rabies Post-Exposure Prophylaxis Referral Program - Impact of Expanded Vaccine Access on Immunization Rates.
Gray JA, Robinson JM, Swift J, Wren N, Kirschke D, Hale N, Cluck D. Am J Infect Control. 2026 Oct 26:S0196-6553(26)00770-4. doi: 10.1016/j.ajic.2026.10.013. Online ahead of print. PMID: 42933661

Erratum to "Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada" [Vaccine 92 (2026) 129122].
Tran S, McClymont E, Blitz S, Barrett J, Bogler T, Boucoiran I, Castillo E, D'Souza R, El-Chaâr D, Fadel S, Kuret V, Poliquin V, Sadarangani M, Scott H, Snelgrove JW, Tunde-Byass M, Money D; COVERED Team. Vaccine. 2026 Oct 31:129306. doi: 10.1016/j.vaccine.2026.129306. Online ahead of print. PMID: 42966687 Free article. No abstract available.

Zoster Vaccination and Dementia: Interpreting the Signal and Testing the Mechanisms.
Rouphael N. Clin Infect Dis. 2026 Oct 28;83(4):632-637. doi: 10.1093/cid/ciag358. PMID: 42253010 Review.

Monitoring of adverse events following 2024-2025 BNT162b2 KP.2 COVID-19 vaccination in the United States.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Sun JW, Dodge LE, Cai S, Zhou L, Wang FT. Vaccine. 2026 Oct 26;95:129296. doi: 10.1016/j.vaccine.2026.129296. Online ahead of print. PMID: 42933241 Free article.

Lack of ancestral SARS-CoV-2 imprinting promotes Omicron sublineage BA.3.2.2 infection in children.
Niu X, Xiong D, He P, Yu L, Li Y, Cai X, An R, Wang Y, Kong R, Yu Y, Wang J, Wang Q, Huang J, Zhang B, Zhu T, Zhao T, Huang J, Jian F, Shao F, Huang Z, Chen X, Shen Z, Jin R, Xie Z, Chen X, Tan X, Cao Y. Nat Microbiol. 2026 Oct 26. doi: 10.1038/s41564-026-02526-w. Online ahead of print. PMID: 42934357

Meningitis burden and vaccine impact in the WHO Western Pacific Region, 1990-2023.
Byun S, Hwang Y, Son Y, Choi T, Kim HJ, Smith L, Woo HG, Nehs CJ, Yon DK, Kang J. J Travel Med. 2026 Oct 30;33(7):taag083. doi: 10.1093/jtm/taag083. PMID: 42730638

T-Cell Response After SARS-CoV-2 Vaccination in Patients With Hematological Malignancy.
Boerenkamp LS, Scheffers N, Brandts L, van Gorkom GNY, Pothast CR, Heemskerk MHM, Wieten L, Van Elssen CHMJ. Eur J Haematol. 2026 Oct 30. doi: 10.1111/ejh.70345. Online ahead of print. PMID: 42961406 Review.

Optimization and miniaturization of a human intestinal organoid neutralization assay for evaluating human norovirus antibody responses.
Ettayebi K, Estes MK, Ramani S, Crawford SE, Boussattach A, Patil K, Borkowski A, Abram ME, Atmar RL. J Virol Methods. 2026 Oct 24;348:115482. doi: 10.1016/j.jviromet.2026.115482. Online ahead of print. PMID: 42925896

Milestone cancer vaccine success leaves hard questions unanswered.
Kaiser J. Science. 2026 Oct 29;394(6823):478-479. doi: 10.1126/science.aen6356. Epub 2026 Oct 29. PMID: 42956139

High *ex vivo* recombination rate of African swine fever virus in porcine alveolar macrophages.
Mészáros I, Olasz F, Miklós I, Göltl E, Oláh B, Zádori Z. Vet Q. 2026 Dec 31;46(1):2740247. doi: 10.1080/01652176.2026.2740247. Epub 2026 Oct 23. PMID: 42909479 Free PMC article.

Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy.
Munblit D, Buonsenso D, Olliaro PL, Semple MG, Greenhawt MJ, Genuneit J, Ashkenazi-Hoffnung L, Wilder-Smith A, Warner JO, Chang AY, Sultan F, Putri ND, Poland GA, Bush A, Boaventura V, Apfelbacher C, Ulloa-Gutierrez R, Watson HR, Oliveira CR, Reyes LF. Clin Infect Dis. 2026 Oct 28;83(4):e892-e899. doi: 10.1093/cid/ciag403. PMID: 42554662 Free PMC article. Review.

Determinants of Measles Vaccine Failure and Breakthrough Infections: A Systematic Review of IgG Avidity Based Immunological Markers and Host Genetic Polymorphisms.
Zaman G, Shabbir S, Rathod D, Sabir A, Sohail F, Abdullah M, Taharat A, Ghauri HF, Basyal S, Parajuli R. Trop Med Int Health. 2026 Oct 29. doi: 10.1111/tmi.70240. Online ahead of print. PMID: 42954314 Review.

T cell metabolic ageing as a factor for therapeutic research.
King E, Zinali Sohanaki B, Schurich A. Clin Exp Immunol. 2026 Oct 27:uxag066. doi: 10.1093/cei/uxag066. Online ahead of print. PMID: 42935129

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

RNA structures regulate norovirus life cycle and enable rational attenuation in vivo.
Hann T, Ökten AB, Filler RB, Wilen CB, Pyle AM. Cell. 2026 Oct 29;189(22):7090-7104.e8. doi: 10.1016/j.cell.2026.07.051. Epub 2026 Aug 19. PMID: 42617594 Free PMC article.

Herd immunity without evidence of viral circulation during seven years of vaccination with Porvac , a subunit vaccine against classical swine fever.
Sordo-Puga Y, Sardina-González T, Pérez-Pérez D, Wong-Rodríguez L, Hernández-García M, Méndez-Orta MK, Santana E, Fuentes Y, Magdariaga A, Vargas-Hernández M, Gil-Morales T, Piñero-Leyva D, Zulueta-Miranda J, Hochman O, Benaragama I, Brawerman G, Ambagala A, Estrada MP, Duarte CA, Rodríguez-Moltó MP, Suárez-Pedroso M. Vaccine. 2026 Oct 24;92:129157. doi: 10.1016/j.vaccine.2026.129157. Epub 2026 Sep 11. PMID: 42727400

RNASTOP: A Deep Learning Framework for mRNA Chemical Stability Prediction and Optimization.
Lin S, Chen J, Sun H, Zhang Y, Yang W, Tan H, Wei DQ, Jiang Q, Xiong Y. Genomics Proteomics Bioinformatics. 2026 Oct 24:qzag109. doi: 10.1093/gpbjnl/qzag109. Online ahead of print. PMID: 42928593 Free article.

Etiology and incidence of diarrhea requiring hospitalization in children under 5 years of age in 31 low- and middle-income countries: Findings from the Global Pediatric Diarrhea Surveillance network, 2017-2022.
Soeters HM, Antoni S, Iyer SS, Weldegebriel G, Biey J, Mwenda JM, Rey-Benito G, Ortiz C, Pastore R, Videbaek D, Singh S, Njambe E, Sangal L, Dhongde D, Grabovac V, Logronio J, Fahmy K, Ghoniem A, Armah G, Dennis FE, Seheri ML, Magagula N, Rakau-Nondela K, Fumian TM, Maciel ITA, Samoilovich E, Semeiko G, Varghese T, Thomas S, Bines JE, Li D, Kabir F, Liu J, Houpt ER, Gautam R, Mirza SA, Vinjé J, Mulders MN, Tate JE, Parashar UD, Platts-Mills JA; Global Pediatric Diarrhea Surveillance network. PLOS Glob Public Health. 2026 Oct 27;6(10):e0006655. doi: 10.1371/journal.pgph.0006655. eCollection 2026. PMID: 42945288 Free PMC article.

Hospital-based surveillance of vaccine-preventable diseases in children: a retrospective study in a Dutch tertiary hospital (2024-2025).
Heemskerk S, Roels V, van Summeren J, Bont LJ, Wildenbeest JG. Vaccine. 2026 Oct 24;95:129187. doi: 10.1016/j.vaccine.2026.129187. Online ahead of print. PMID: 42925772

Pneumococcal vaccine after hematopoietic cell transplantation: a rapid review of four-dose pneumococcal conjugate vaccine schedules.
Kamitani E, Kobayashi M, Gebremichael F, Lee J, Rivera JC, Rodriguez EM, Silva JBB, Childs L, Taliano J, Kamboj M. Vaccine. 2026 Oct 31;96:129299. doi: 10.1016/j.vaccine.2026.129299. Online ahead of print. PMID: 42966040 Review.

Secretory expression of tetrameric neuraminidase enhanced by signal peptide optimization elicits robust immunity against influenza infection in mice.
Deng L, Ye X, Chen X, Hu X, Zhang X, Han Z, Sun C. Vaccine. 2026 Oct 24;92:129118. doi: 10.1016/j.vaccine.2026.129118. Epub 2026 Sep 5. PMID: 42700747

The case for model-informed vaccine development.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Bai JPF, Beigmohammadi F, Craig M, Dalton M, Desikan R, Easlick T, Gazeau S, Heffernan J, Kirpichnikova A, Padmanabhan P, Sachs JR, Sher A, Skibinski D, Smith AM. Vaccine. 2026 Oct 24;92:128780. doi: 10.1016/j.vaccine.2026.128780. Epub 2026 Sep 21. PMID: 42767025

A mucosal prime-systemic boost strategy using a glycoengineered bacterial membrane vesicle vaccine elicits protective mucosal immunity against pneumococci in mice.
Nakao R, Uchiyama H, Yamaguchi T, Abe K, Takahashi A, Kimijima M, Kuroda E, Hamaguchi S, Kudo T, Akeda Y. Vaccine. 2026 Oct 24;92:129142. doi: 10.1016/j.vaccine.2026.129142. Epub 2026 Sep 18. PMID: 42759251 Free article.

Bridging the translational gap: an operational classification and quantitative framework for accelerating enteric vaccine research using animal models.
Koley H, Mukherjee A, Mukhopadhyay AK, Das S, Howlader DR. Vaccine. 2026 Oct 24;92:129167. doi: 10.1016/j.vaccine.2026.129167. Epub 2026 Sep 23. PMID: 42784864 Review.

Oral vaccine delivery systems: Gastrointestinal barriers, gut microbiota, and emerging engineering strategies.
Wang X, Pan W, Huang J, Zhou Y, Nalinratana N, Rojsitthisak P, Lin Y, Zhao K. Cell Rep. 2026 Oct 27;45(10):118038. doi: 10.1016/j.celrep.2026.118038. Epub 2026 Sep 28. PMID: 42789394 Free article. Review.

Infection history and TCR sequence features shape the breadth of TCR cross-reactivity.
Gaevert JA, Mayer-Blackwell K, Pogorelyy MV, Schattgen SA, Kirk AM, Duan S, Van de Velde LA, Souquette AH, Awad W, St James DG, Clark NA, Duque DL, Allen EK, Lythe G, Molina-Paris C, Crawford JC, Fiore-Gartland A, Bradley P, Minervina AA, Thomas PG. Cell Rep. 2026 Oct 24;45(11):118182. doi: 10.1016/j.celrep.2026.118182. Online ahead of print. PMID: 42925505 Free article.

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.
Idriss J, Kalash S, Abu Faraj J, Nolan L, Bechnak K, Rouphael N. Clin Infect Dis. 2026 Oct 28;83(4):618-624. doi: 10.1093/cid/ciag445. PMID: 42464875 Review.

Correction to: Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults 50 Years.
[No authors listed] Open Forum Infect Dis. 2026 Oct 31;13(11):ofag695. doi: 10.1093/ofid/ofag695. eCollection 2026 Nov. PMID: 42967052 Free PMC article.

Combating Infectious Disease Challenges: Have We Gone Twenty Steps Forward or Backward?
Kavanagh KT, Webley W, Cimiotti JP, Pontus C, Cormier LE. J Patient Saf. 2026 Oct 23. doi: 10.1097/PTS.0000000000001605. Online ahead of print. PMID: 42925011

Vaccine- and infection-induced pneumococcal and DENV-NS1 antibodies reveal differential transplacental transfer and maternal-infant early exposure burden.
Polanía-Espinosa D, Salgado D, Vega R, Castañeda-Uvajoa D, Cubillos-Villada S, Rodríguez J, Narváez CF. Vaccine. 2026 Oct 24;92:129138. doi: 10.1016/j.vaccine.2026.129138. Epub 2026 Sep 14. PMID: 42735604 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Linker-mediated single-transcript mRNA vaccine expressing virus-like particles of enterovirus D68.
Kunishima Y, Senpuku K, Taniguchi K, Kataoka-Nakamura C, Hirai T, Yoshioka Y. Vaccine. 2026 Oct 24;92:129136. doi: 10.1016/j.vaccine.2026.129136. Epub 2026 Sep 11. PMID: 42721891 Free article.

Physicians struck-off the professional registers during COVID-19 pandemic: is their reinstatement risk-free?
Gristina GR, Mistraletti G. J Anesth Analg Crit Care. 2026 Oct 28;6(1):134. doi: 10.1186/s44158-026-00468-7. PMID: 42947184 Free PMC article.

Changes in attitudes toward the HPV vaccine in Kenya.
Moucheraud C, Miao J, Ochieng E, Zhang S, Ganda G, Golub G, Hoffman RM, Szilagyi PG, Suen SC. PLOS Glob Public Health. 2026 Oct 23;6(10):e0007508. doi: 10.1371/journal.pgph.0007508. eCollection 2026. PMID: 42912706 Free PMC article.

Microdroplet hemagglutination assay for virus-like particle (VLP) quantification.
Marcali M, Elbuken C, Ramirez E, Chakraborty M, Aucoin M, Ren CL. Lab Chip. 2026 Oct 26. doi: 10.1039/d6lc00499g. Online ahead of print. PMID: 42932171

Cryptococcus neoformans GXM Mimotopes: Bioactivity and Modulation of Human Inflammatory Response and Oxidative Burst in vitro.
da Silva PR, de Castro KG, Silva Teixeira DN, Prereira HSA, Vieira CU, Goulart Filho LR, de Paula Rogério A, Vieira JG, Rodrigues LP. Eur J Pharmacol. 2026 Oct 26:179471. doi: 10.1016/j.ejphar.2026.179471. Online ahead of print. PMID: 42933759 Free article.

Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged 50 Years: A Phase 3, Randomized, Noninferiority Trial.
Bonten M, Essink B, Hanning N, Leroux-Roels I, Masuet-Aumatell C, Martinez SN, Hailemariam HA, Jandari G, Kwo Ton Ge Jua P, Servais C, Valenciano S, Jastorff AM, Cárdenas V, Van der Wielen M. Clin Infect Dis. 2026 Oct 28;83(4):e867-e877. doi: 10.1093/cid/ciag344. PMID: 42240564 Free PMC article. Clinical Trial.

Influenza A Virus at the Exhibition Swine-Human Interface in the USA.
McBride DS, Nelson MI, Cochran HJ, Nicholson HN, Ohl EM, Jang Y, Zanders N, Cui D, Di H, Davis CT, Barnes JR, Wilson MM, Kirby MK, Bowman AS, Nolting JM. Zoonoses Public Health. 2026 Oct 30. doi: 10.1111/zph.70096. Online ahead of print. PMID: 42961404

Innovation, development, and licensure of improved influenza vaccines: the way forward.
Ostrowsky JT, Gellin BG, Cavaleri M, Bresee JS, Venkayya R, Cox RJ, Schultz-Cherry S, Hollingsworth R, Subbarao K, Cohen C, Settembre EC, Belongia E, McCauley JW, Rappuoli R, Cowling BJ, Taaffe J, Vestin NC, Mehr AJ, Ulrich AK, Osterholm MT, Moore KA. Vaccine. 2026 Oct 24;92:129135. doi: 10.1016/j.vaccine.2026.129135. Epub 2026 Sep 18. PMID: 42759246 Free article. Review.

Early innate immune signatures correlate with Ad26.COV2.S vaccine immunogenicity and protective efficacy.
Colarusso A, Stephenson KE, Collier A-RY, Wegmann F, Zahn R, Aid M, Barouch DH. J Virol. 2026 Oct 26:e0149426. doi: 10.1128/jvi.01494-26. Online ahead of print. PMID: 42929544 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

The AGS Older Adults Vaccine Initiative: Findings From Seven Participating Health Systems.
Farrell TW, Amjad NA, Khan A, Garcia JIP, Puckett M, Soffer J, Sultan FB, Varghese D, Walke LM, Brening N, Chung TH, De Lima B, Le YC, Panchal V, Simpson M, Tambe V, Vaughan CP, Wills S, Lundebjerg NE, Brangman SA. J Am Geriatr Soc. 2026 Oct 28. doi: 10.1111/jgs.70770. Online ahead of print. PMID: 42947551

A seven-valent norovirus mRNA vaccine elicits robust humoral responses in preclinical models.
Bystol K, O'Donnell G, Hartwig S, David C, Galli J, Warren C, Go G, Obed B, Lago A, Citron M, Fulton CM, Phan T, Gaspar JM, Singh P, Fridman A, Shu Y, Wei J. J Virol. 2026 Oct 29:e0112826. doi: 10.1128/jvi.01128-26. Online ahead of print. PMID: 42954484 Free article.

Prioritising environmental determinants in health technology assessment: a framework for integrating environmental considerations into health-care decision making.
Gao L, Hensher M. Lancet Planet Health. 2026 Oct 27:101543. doi: 10.1016/j.lanplh.2026.101543. Online ahead of print. PMID: 42945980 Free article. Review.

Comparison of memory B cell responses in Bangladeshi adults following single-dose and two-dose oral cholera vaccine, Shanchol(TM).
Dash P, Akter A, Jahan N, Bhuyan GS, Karmakar PC, Ahsan MA, Alam MM, Aktar A, Uddin T, Calderwood SB, Chowdhury F, Khan AI, Saha A, Ryan ET, Bhuiyan TR, Akter A, Qadri F. Int J Infect Dis. 2026 Oct 31:109219. doi: 10.1016/j.ijid.2026.109219. Online ahead of print. PMID: 42966445 Free article.

In silico and in vitro immunogenicity risk assessment of process- and product-related protein impurities reported in adenoviral-vectored COVID-19 vaccines.
De Groot AS, Gabriel B, McAllister M, Garcia T, Jawa V. J Pharm Sci. 2026 Oct 23;115(12):104562. doi: 10.1016/j.xphs.2026.104562. Online ahead of print. PMID: 42918575 Free article.

Leveraging information technology to promote the safe and effective use of vaccines.
Darby A, Moore C, Mullen C, Rivard K. Am J Health Syst Pharm. 2026 Oct 23;83(21):e830-e842. doi: 10.1093/ajhp/zxag008. PMID: 41525346 Free article.

Influence of vaccine delivery route on immune imprinting in influenza vaccination.
Thakkar V, Aryan Y, Gautam S, Joshi R, Kumar S, Joshi D. Vaccine. 2026 Oct 24;92:129109. doi: 10.1016/j.vaccine.2026.129109. Epub 2026 Sep 7. PMID: 42705168 Free article. Review.

COVID-19 vaccine uptake among individuals with Down syndrome in the Unites States.
Nian H, Ding T, Lee RL, Gebretsadik T, Ammar L, Enujioke SC, McCoy AB, Sengstack DG, Riddell CA, Hartert TV, Wu P. Vaccine. 2026 Oct 24;92:129128. doi: 10.1016/j.vaccine.2026.129128. Epub 2026 Sep 3. PMID: 42691822 Free article.

Identification of peptide epitopes in major antigens of Yersinia pestis from infected humans and immunised mice.
Echenique-Rivera H, Simon A, Spadoni JL, Holenya P, Schnatbaum K, Meyniel JP, Andriatefy O, Rajerison M, Pizarro-Cerdá J, Demeure C, Schoenhals M, Zagury JF. EBioMedicine. 2026 Oct 29;133:106523. doi: 10.1016/j.ebiom.2026.106523. Online ahead of print. PMID: 42956539 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada.
Tran S, McClymont E, Blitz S, Barrett J, Bogler T, Boucoiran I, Castillo E, D'Souza R, El-Chaâr D, Fadel S, Kuret V, Poliquin V, Sadarangani M, Scott H, Snelgrove JW, Tunde-Byass M, Money D; COVERED Team. Vaccine. 2026 Oct 24;92:129122. doi: 10.1016/j.vaccine.2026.129122. Epub 2026 Sep 3. PMID: 42691825 Free article.

Antibody 3CF5 neutralizes historical and emerging H5Nx influenza viruses by targeting a conserved non-receptor-binding hemagglutinin epitope.
Liang H, Niu C, Cheng Y, Liew KY, Qu L, Zheng Z, Yang W, Wang Q, Wei L, Liu B, Hu F, Xing C, Chen J, Pan W, Li P, Tan YJ, Xiong X, Chen L, Niu X. Cell Rep. 2026 Oct 29;45(11):118180. doi: 10.1016/j.celrep.2026.118180. Online ahead of print. PMID: 42955944 Free article.

Preclinical toxicity and immunogenicity of a quadrivalent recombinant influenza hemagglutinin vaccine (SCVC101) in rhesus monkeys.
Guo J, Dai C, Huang Y, Dai J, Zhang W, Feng J, Chen L, Ma X, Wen Y, Peng T, Xu Y, Yang W. Vaccine. 2026 Oct 24;92:129137. doi: 10.1016/j.vaccine.2026.129137. Epub 2026 Sep 13. PMID: 42732725

The first complete genome sequence and pathogenicity characterization of a reassortant avian orthoreovirus genotype Ⅰ subvariant strain.
Chen J, Pan Y, Meng E, Wang C, Zhao X, Zhang Q, Hao X, Wang J, Li G, Yi F, Liu A. Vet Microbiol. 2026 Oct 27;323:111276. doi: 10.1016/j.vetmic.2026.111276. Online ahead of print. PMID: 42950768 Free article.

A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention.
Li D, Wang H, Guo J, Leng F, Zhi X, Gong M, Zeng M, Liu K, Sun Y, Li Y, Zhang Y, Xu J. Sci Adv. 2026 Oct 30;12(44):eaee7661. doi: 10.1126/sciadv.aee7661. Epub 2026 Oct 28. PMID: 42950024 Free PMC article.

Antibody-mediated functional responses induced by the SchistoShield schistosomiasis vaccine in disease-naive and endemic human populations.
Kalyanasundaram A, Kifle DW, Davis J, Balkhi MY, Arya A, Mayer BT, Lemire G, Krishnappa D, Siribie M, Jeon H, Tadesse BT, Rakotozandrindrainy N, Razafimanantsoa R, Noellie HB, Ouedraogo NI, Diarra A, Velavan TP, Gray SA, Lee J, Rakotozandrindrainy R, Sirima SB, Jackson LA, Marks F, Carter D, Siddiqui AA. Vaccine. 2026 Oct 24;92:129129. doi: 10.1016/j.vaccine.2026.129129. Epub 2026 Sep 7. PMID: 42705169 Free article.

Microneedle-Based Oral Mucosal Vaccines: Mechanisms, Challenges, and Emerging Strategies.
Hu O, Huang L, Huang L, Yang J, Tang Y, Pan S, Pu M, Xu J, Xiang L. ACS Appl Mater Interfaces. 2026 Oct 30. doi: 10.1021/acsami.6c16754. Online ahead of print. PMID: 42956328

Genetic variation in HLA, IGKV, and HHEX loci influences mRNA vaccine-induced humoral protection against COVID-19.
Puzek B, Wratil PR, Janke C, Le Thi TG, Rubio-Acero R, Lupoli G, Schoof IC, Stern M, Zhelyazkova A, Rech J, Choukér A, Koletzko B, Wieser A, Török HP, Castelletti N, Keppler OT, Geldmacher C, Hornung V, Zeggini E, Adorjan K, Hoelscher M, Koletzko S, Kim-Hellmuth S. Cell Rep. 2026 Oct 27;45(10):117981. doi: 10.1016/j.celrep.2026.117981. Epub 2026 Sep 30. PMID: 42814572 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Acute immunometabolic reprogramming following clade C HIV immunization in rhesus macaques.
Arroyo L, Raeman R, Iyer SS. Vaccine. 2026 Oct 24;92:129115. doi: 10.1016/j.vaccine.2026.129115. Epub 2026 Sep 4. PMID: 42696823 Free article.

The status quo and evolution of glycoconjugates for cancer immunotherapy.
Singh Y, Kamra M. Glycoconj J. 2026 Oct 28;43(1):32. doi: 10.1007/s10719-026-10227-z. PMID: 42955118 Free PMC article. Review.

Rationally designed negatively charged lipid nanoparticles reduce systemic reactogenicity of mRNA vaccines while preserving immunogenicity.
Karaki T, Inoue W, Gis T, Shichinohe S, Watanabe T, Hirai T, Yoshioka Y. J Control Release. 2026 Oct 24;400(Pt A):115490. doi: 10.1016/j.jconrel.2026.115490. Online ahead of print. PMID: 42926017 Free article.

Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.
Amoia CF, Misinzo G, Munir M. Trop Dis Travel Med Vaccines. 2026 Oct 30;12(1):35. doi: 10.1186/s40794-026-00320-4. PMID: 42963803 Free PMC article. Review.

An alpha1D-adrenergic receptor vaccine protects against HFpEF in mice.
Wu J, Shi D, Wang Y, Ma Q, Chen H, Huang J, Ma W, Lama E, Liu C, Gao R, Wang Y, Ni X, Liao Y, Qiu Z, Zhou Z. Int Immunopharmacol. 2026 Oct 24;191(Pt 1):117604. doi: 10.1016/j.intimp.2026.117604. Online ahead of print. PMID: 42925653

Automated deep learning tool for robust colony counting in vaccine immunogenicity bioassays.
Ma C, Cheng YW, Xie J, Vazvaei-Smith F, Helmy R, Wang S, Xu W. Bioanalysis. 2026 Oct 28:1-12. doi: 10.1080/17576180.2026.2752782. Online ahead of print. PMID: 42948866

Perspectives on Immunotherapeutics for Opioid Use Disorder and Overdose Prevention From People Who Use Opioids (PWUOs).
Herberholz ES, Panlilio LV, Luba R, Comer SD, Pravetoni M, Weiss ST, Beckwith BD, Wolchok RE, Epstein DH. J Addict Med. 2026 Oct 28. doi: 10.1097/ADM.0000000000001783. Online ahead of print. PMID: 42956268

Broadening the tumor antigens panorama for cancer vaccines - All the way to the dark matter of the genome.
Di Giacomo AM, Anichini A, Noviello TMR, Chiappinelli KB, Weller M, Ibrahim R, Lahn M, Smith M, Eggermont AMM, Fox BA, Maio M. Eur J Cancer. 2026 Oct 24;249:117796. doi: 10.1016/j.ejca.2026.117796. Online ahead of print. PMID: 42967454 Free article. Review.

Neoantigen evolution in cancer: immunoediting, immune escape, and future vaccine strategies.
Martínez-Cortés F, Valle JG, Maruri J, Martínez-Zarco BA, Domínguez-Romero AN, Gevorkian G, Manoutcharian K. Biochim Biophys Acta Rev Cancer. 2026 Oct 30:189741. doi: 10.1016/j.bbcan.2026.189741. Online ahead of print. PMID: 42962941 Review.

In Silico Design and Immunogenicity Studies of Two Multi-Epitope Vaccines against *Klebsiella pneumoniae*.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Vicente-Pazos M, López-Siles M, McConnell MJ. Comput Struct Biotechnol J. 2026 Oct 28;35(1):0232. doi: 10.34133/csbj.0232. eCollection 2026. PMID: 42953336 Free PMC article.

Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted influenza A (H5N8) vaccine.
Maria DA, Martins IM, Porto GPM, Villas-Boas IM, Leite GA, de Oliveira Marinho da Silva L, Dos Santos RMV, de Carvalho Mello IMVG, Eto SF, Goldfeder MB, Junior REC, Rondon GG, Sant'anna MB, Almeida TC, da Silva DF, Picolo G, Faria F, Baptistão CCS, Botosso VF, Kallás EG; Non-Clinical Study Working Group; Chudzinski-Tavassi AM. Vaccine. 2026 Oct 24;92:129049. doi: 10.1016/j.vaccine.2026.129049. Epub 2026 Sep 4. PMID: 42696822

Knowledge as a predictor of parental vaccine hesitancy during children's first year of life.
Almeida MG, Alves de Oliveira BF, de Melo Júnior EB, de Araújo Rodrigues AR, Lugo NF, Moura Borges PT, de Sousa Neto AR, Evangelista de Araújo TM. Vaccine. 2026 Oct 24;92:129127. doi: 10.1016/j.vaccine.2026.129127. Epub 2026 Sep 8. PMID: 42710148 Free article.

Group A streptococcus vaccine strategies: virulence targets, resistance constraints and complementary control measures.
Agarwal M, Khataniar A, Rajkhowa S. Immunol Res. 2026 Oct 29;74(1):131. doi: 10.1007/s12026-026-09865-0. PMID: 42955549 Review.

Sono-Tribocatalytic Whole Tumor Cell Vaccine Enables Ultrasound-Controlled Immune Boosting for Enhanced Anti-Tumor Immunity.
Ren H, Wu Q, Yang W, Tang Z, Xia L, Wu C, Dai X, Huang H, Chen Y. Angew Chem Int Ed Engl. 2026 Oct 26;65(44):e5688540. doi: 10.1002/anie.5688540. Epub 2026 Sep 11. PMID: 42728564

Effect of Foetal Bovine Serum in Oil-Adjuvanted Vaccines on Spinal Deformities and Growth in Atlantic Salmon (Salmo salar).
Thorarinsson R, Hansen T, Høstmark O, Einen AC, Hodneland K, Villoing S, Frost P, Midtbø H, da Silva RB. J Fish Dis. 2026 Oct 30:e70318. doi: 10.1111/jfd.70318. Online ahead of print. PMID: 42963597

Bacterial Surfaces and Barriers: Biogenesis and Pathogen-Host Interactions.
Bartholomew-Schoch J, Finnie JK, Gahlmann A, Columbus L. Chem Rev. 2026 Oct 28;126(20):11082-11151. doi: 10.1021/acs.chemrev.5c01068. PMID: 42949064 Free PMC article. Review.

Narrative dynamics and algorithmic amplification of childhood vaccine misinformation on Brazilian TikTok.
Castro TH, Barros JN, Assis DC, Holanda DAM, Cardoso MVLML, Martins MC, Lira ALBC, Coelho MMF. Rev Gaucha Enferm. 2026 Oct 26;47:e20260083. doi: 10.1590/1983-1447.2026.20260083.en. eCollection 2026. PMID: 42961257 Free article. English, Portuguese.

The global landscape of Campylobacter: genomic epidemiology, AMR trends, and the path to vaccine development.
Downham RL, Dombach JL, MacArthur JL, Norris MH, Ewers EC, Le Saux OLP, Tribble DR, Kamau E. Clin Microbiol Rev. 2026 Oct 28:e0019126. doi: 10.1128/cmr.00191-26. Online ahead of print. PMID: 42949275 Review.

Efficacy and economic evaluation of a novel genotype VII marker vaccine for Newcastle disease in layers.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Dai Y, Gao J, Zhu Q, Xu F, Cheng B, Shen X, Liu X, Ji Y. Vet Res Commun. 2026 Oct 23;51(1):14. doi: 10.1007/s11259-026-11591-9. PMID: 42909674

In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans.
Kent SJ, Li S, Amarasena TH, Reynaldi A, Leeming MG, Juno JA, Wheatley AK, Deliyannis G, Godfrey DI, Nolan T, Pouton CW, Davenport MP, Ju Y. ACS Nano. 2026 Oct 27;20(42):28329-28342. doi: 10.1021/acsnano.6c09226. PMID: 42937588 Free PMC article.

Efficacy of ShotBlocker for Pain Relief in Infants During Vaccination: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Madkour S, Baradwan S, Mahmoud AMA, Ahmed MF, Abdelgawad AY, Agaba NFM, Nasr HM, Okda HT, Mohammed AS, Ahmed AM, Mohamed AH, Alshamrani NM, Elbeltagy ESF, Abdelhakim AM, Hamza HM. J Pediatr Health Care. 2026 Oct 24:S0891-5245(26)00370-6. doi: 10.1016/j.pedhc.2026.09.008. Online ahead of print. PMID: 42927481

Real-World Effectiveness of International Border Health Interventions in Mitigating the Spread of SARS-CoV-2 During the First Years of the COVID-19 Pandemic, 2020-2023: A Systematic Review.
Shearer E, Roy SC, Ahmed F, Wuyke G, Edelson PJ, Palo M, Gearhart S, Warren K, Akinkugbe O, Ramirez M, Zviedrite N, Alvarado-Ramy F, Brown C, Gertz AM. Health Secur. 2026 Oct 28:23265094261492166. doi: 10.1177/23265094261492166. Online ahead of print. PMID: 42952153

Conspiracy Theories Dominate Spanish Antivaccine Narratives on TikTok: A Content Analysis of Algorithmic and Linguistic Evasion.
Alfred OG, Elías C, Catalan-Matamoros D. Health Commun. 2026 Oct 29:1-12. doi: 10.1080/10410236.2026.2745718. Online ahead of print. PMID: 42953988

Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort.
Sanborn J, Robertson MM, Penrose K, Rane M, Piltch-Loeb R, Parcesepe AM, Nash D. Vaccine. 2026 Oct 24;92:129126. doi: 10.1016/j.vaccine.2026.129126. Epub 2026 Sep 6. PMID: 42702142 Free article.

Clinical development of human vaccine candidates against Shigella flexneri: a systematic review of clinical trials.
Rostamian M, Chegene Lorestani R, Shahbazi T, Mohammadi P, Shahbazi S, Ghadiri K. Vaccine. 2026 Oct 24;92:129134. doi: 10.1016/j.vaccine.2026.129134. Epub 2026 Sep 22. PMID: 42771939

Ionic liquid-mediated cellular loading for whole tumor cell vaccines.
Rodrigues D, Mukherji M, Park KS, Joshi M, Kapsalis L, Shaha S, Bibbey MG, Erdi M, Mitragotri S. Proc Natl Acad Sci U S A. 2026 Nov 3;123(44):e2604066123. doi: 10.1073/pnas.2604066123. Epub 2026 Oct 28. PMID: 42949972

Understanding pathogenesis of and BCG vaccine efficacy against high, moderate, and low transmissible Mycobacterium tuberculosis strains in mice.
Khatri B, Salguero FJ, Goyal M, Dagg B, Wandiga S, Ho MM. Vaccine. 2026 Oct 24;92:129116. doi: 10.1016/j.vaccine.2026.129116. Epub 2026 Sep 10. PMID: 42721892

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Unequal Burdens of Health Misinformation: Disparities in Exposure, Susceptibility, and Outcomes.
Tsichlis JT, Victorson DE. J Racial Ethn Health Disparities. 2026 Oct 24. doi: 10.1007/s40615-026-03163-z. Online ahead of print. PMID: 42926243 Review.

Perceived influence of media campaigns and immunization awareness in rural Muzaffarabad, Azad Jammu and Kashmir: A cross-sectional evaluation of selection Bias in digital survey methodology.
Shah SMH, Fatima T, Ullah AA. Vaccine. 2026 Oct 24;92:129173. doi: 10.1016/j.vaccine.2026.129173. Epub 2026 Sep 18. PMID: 42759247

Promoting a personalized vaccine information website through social media and local outreach: a dissemination and implementation study.
Forr A, Salmon DA, Markalanda SH, Joseph A, Aeschliman R, Lawler J, Phillips L, Moore J, Brewer J, Goryn M, Dudley MZ. Vaccine. 2026 Oct 24;92:129161. doi: 10.1016/j.vaccine.2026.129161. Epub 2026 Sep 18. PMID: 42759248

Safety and immunogenicity of an adenoviral-vectored vaccine against Crimean-Congo haemorrhagic fever in the UK (CCHF01): an open-label, first-in-human, non-randomised, phase 1 clinical trial.
Pollock KM, Saunders JE, Fowler J, Camara S, Kakai I, Eordogh A, Plested G, Green CM, da Silva CF, de Whalley P, Islam MK, Marchevsky NG, Belij-Rammerstorfer S, Lambe T; CCHF01 Study Team. Lancet Infect Dis. 2026 Oct 23:S1473-3099(26)00471-8. doi: 10.1016/S1473-3099(26)00471-8. Online ahead of print. PMID: 42914993 Free article.

Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability.
Zhao GX, Li PL, Yuan BY, Luo QH, Li T, Ma HY, Huang RJ, Bu GL, Xie C, Wu PH, Zhou H, Du WT, Wang J, Fang DJ, Zeng MS, Dong HH, Feng GK, Zhong Q, Sun C. Cell Rep. 2026 Oct 27;45(10):118072. doi: 10.1016/j.celrep.2026.118072. Epub 2026 Sep 26. PMID: 42800025 Free article.

Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study.
Aldali J, Elsokkary E, Alnajdi G, Maghrabi M, Subh R, Alakkasi G, Yati SA, Alzakari M. PLoS One. 2026 Oct 27;21(10):e0360528. doi: 10.1371/journal.pone.0360528. eCollection 2026. PMID: 42945161 Free PMC article.

Prospective assessment of reactogenicity and disease activity after recombinant zoster vaccination in Japanese patients with inflammatory bowel disease.
Omori M, Shibuya T, Ishino H, Orikasa M, Odakura R, Koma M, Ito K, Maruyama T, Nomura K, Nomura O, Ishikawa D, Osada T, Hojo M, Nagahara A. Digestion. 2026 Oct 29:1. doi: 10.1159/dig/acmag035. Online ahead of print. PMID: 42956107 Free article.

Evaluation of the efficacy and duration of immunity of a bivalent subunit vaccine containing porcine circovirus type 2a and type 2d antigen.
Kaiser TJ, Jarrett A, Johnson W, Hinds M, Alonso C, Dorr PM, Leite FL, Eichmeyer M. Vaccine. 2026 Oct 24;92:129159. doi: 10.1016/j.vaccine.2026.129159. Epub 2026 Sep 12. PMID: 42732726

Immunogenicity of norovirus VP1-expressing silkworm (Bombyx mori) pupae as an edible vaccine candidate.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Sasaki T, Masuda A, Lee JM, Tamiya S, Mikaki Y, Naitou K, Taniguchi M, Kimura A, Chieda Y, Ushijima H, Sakon N, Sato S, Ebihara T, Mon H, Kusakabe T, Miyata T. Vaccine. 2026 Oct 24;92:129108. doi: 10.1016/j.vaccine.2026.129108. Epub 2026 Sep 18. PMID: 42759244 Free article.

Advancing modern glycoconjugate vaccines: From synthetic glycans to novel conjugation approaches and carrier systems.
Bordoni V, Adamo R. Curr Opin Chem Biol. 2026 Oct 23;95:102793. doi: 10.1016/j.cbpa.2026.102793. Online ahead of print. PMID: 42914842 Free article. Review.

Exercise and vaccine immune response: A scoping review exploring the underlying immunological mechanisms.
Byrne C, Doran C. Vaccine. 2026 Oct 31;96:129302. doi: 10.1016/j.vaccine.2026.129302. Online ahead of print. PMID: 42966038 Review.

A new semi-automated, motility-based screening assay for discovery of compounds with activity against the juvenile stage of Fasciola hepatica.
Bernal A, Gliga DS, Colangeli G, Preza M, Irobalieva RN, Frey CF, Hemphill A, Lundström-Stadelmann B, Wiedemar N. PLoS Negl Trop Dis. 2026 Oct 26;20(10):e0014491. doi: 10.1371/journal.pntd.0014491. eCollection 2026 Oct. PMID: 42932394 Free PMC article.

An mRNA-lipid nanoparticle vaccine against H5N1 influenza virus protects lactating dairy cows from infection.
Santos JJS, Souza CK, Zanella GC, Goulart DB, Arruda B, Boggiatto P, Palmer MV, Snyder CA, Kristula MA, Dickens C, Webb TL, Atkinson RK, Dadonaite B, Dwivedi G, Alameh MG, Hunter CA, Murphy LA, Bloom JD, Weissman D, Althouse GC, Baker AL, Hensley SE. Nat Biotechnol. 2026 Oct 28. doi: 10.1038/s41587-026-03343-6. Online ahead of print. PMID: 42951950

Trust in Vaccine Information Sources, Perceived Message Credibility, Healthcare Provider Recommendations, and Influenza Vaccine Hesitancy and Uptake Among Rural Adults in Indiana.
Laily A, Jo S, Xu D, Coddington JA. J Community Health Nurs. 2026 Oct 30:1-13. doi: 10.1080/07370016.2026.2754469. Online ahead of print. PMID: 42963195

Neisseria gonorrhoeae: a historical model for host adaptation.
Metaane S, Seifert HS. J Bacteriol. 2026 Oct 29:e0042026. doi: 10.1128/jb.00420-26. Online ahead of print. PMID: 42954803 Free article. Review.

An investigation into post-pandemic ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations.
Scott M, Browning L, Roberts T, De Boer J, Richardson Z, Gada L. Epidemiol Infect. 2026 Oct 26;154:e139. doi: 10.1017/S0950268826102180. PMID: 42929057

Strengthening post-market COVID-19 vaccine safety surveillance and research: An interpretive description study from Kenya, South Africa, and Canada.
Naz AliSher A, Shaik S, Myburgh N, Ndaba N, Hinga A, Okore W, Sang S, Siraj S, Qwabi T, Gutu K, Matano A, Di Castri A, Kochhar S, Kagucia EW, Dangor Z, Cutland CL, Top KA; International Network of Special

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Immunization Services (INSIS) Investigators. PLOS Glob Public Health. 2026 Oct 27;6(10):e0006142. doi: 10.1371/journal.pgph.0006142. eCollection 2026. PMID: 42945272 Free PMC article.

Integrated immunoinformatics and molecular dynamics approaches reveal a promising multi-epitope vaccine against hantavirus.
Ullah S, Tonks A, Maya-Ramírez CE, Abdullah S, Khalil S, Tonni TJ, Hasan MM, Ahmad A. In Silico Pharmacol. 2026 Oct 25;14(3):273. doi: 10.1007/s40203-026-00782-6. eCollection 2026. PMID: 42935623

Autologous erythrocyte microparticles drive antitumour T cell immunity via haem-mediated dendritic cell activation.
Tang K, Liang Y, Sun W, Zheng X, Lu S, Chen Z, Yan Z, Liu S, Liu Y, Chen Y, Deng J, Zhang H, Ma J, Chen J, Zhou Y, Lv J, Huang B. Nat Biomed Eng. 2026 Oct 23. doi: 10.1038/s41551-026-01795-4. Online ahead of print. PMID: 42919905

DUMP Cascade-Oriented MnOx@MSN Nanoadjuvant for Subunit Vaccine Antigen Delivery and Immune Potentiation.
Yin C, Zhang J, Pen L, Chen R, Rehman SU, Asif M, Li Z, Xia H, Shao Y, Zhang L, Wang J, Ma K. ACS Appl Bio Mater. 2026 Oct 28. doi: 10.1021/acsabm.6c01329. Online ahead of print. PMID: 42949546

Physicochemical design principles for B cell targeted acetalated dextran microparticles in antigen-specific tolerance for multiple sclerosis.
Clark KA, Barbery BG, Lopez AM, Hendricksen AT, Lukesh NR, Ontiveros-Padilla L, Murphy CT, Williamson GL, Ly SA, Shilling KE, Woodring RN, Mendell SE, Hardaway LG, Tisch RM, Bachelder EM, Ainslie KM. Biomater Sci. 2026 Oct 23. doi: 10.1039/d6bm01160h. Online ahead of print. PMID: 42922362 Free PMC article.

Mitigation of imprinted antibody responses against COVID-19 in highly vaccinated older adults.
Morse RB, Egan DJS, Cheng MTK, Altaf M, Kamelian K, Gallagher C, Gutierrez LC, Sokolova O, Bradley JR, Smith KGC, Meloy S, Ison G, Furlong A, Scholtes I, Le Gresley E, Doffinger R, Tan CW, Gupta RK. J Infect. 2026 Oct 30:106883. doi: 10.1016/j.jinf.2026.106883. Online ahead of print. PMID: 42962933 Free article.

Effectiveness of an Inactivated Quadrivalent Influenza Vaccine in Children and Pregnant Women in Rural Bangladesh: A Phase IV Double-Blind, Cluster-Randomized Trial.
Zaman K, Haque W, Trieu MC, Bansal A, Bonnevie A, Lartey S, Goswami DR, Aktar MS, Arifuzzaman ASM, Brokstad KA, Yddal I, Borlaug A, Rana S, Hasan MK, Basunia AH, Rahman M, Cox RJ, Clemens JD. Int J Infect Dis. 2026 Oct 26:109209. doi: 10.1016/j.ijid.2026.109209. Online ahead of print. PMID: 42933529 Free article.

Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis.
Rahman MA, Kabir L, Ahmed N, Barua A, Hasan M, Mahdeen AA. PLoS One. 2026 Oct 23;21(10):e0361136. doi: 10.1371/journal.pone.0361136. eCollection 2026. PMID: 42912726 Free PMC article.

Where intention goes, responsibility flows: Grounding AI accountability in the machine learning paradigm.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Hilbert M. Proc Natl Acad Sci U S A. 2026 Nov 10;123(45):e2610670123. doi: 10.1073/pnas.2610670123. Epub 2026 Oct 30. PMID: 42961910

Aromaticity at spike position 456 affects functional immunogenicity of SARS-CoV-2 Omicron variant receptor-binding domain.
Peng D, Chen Z, Fu M, Hong W, Dai M, Zeng H, Lin S, Lei H, Yang J, Shi J, Huang X, Ye C, Qin F, Zhang Y, Hao Y, Wang B, Ren W, Chen L, Liu J, Alu A, Lu Y, Du X, Li J, Shi H, Wei Y, Chen Y, Lu S, He C, Lu G, Wei X. Signal Transduct Target Ther. 2026 Oct 28;11(1):496. doi: 10.1038/s41392-026-02939-3. PMID: 42957648 Free PMC article.

Gene conversion is a key driver of diversity hotspots in *Mycobacterium tuberculosis* antigens and virulence-associated loci.
Marin MG, Quinones-Olvera N, Jin H, Harris MA, Jeffrey BM, Rosenthal A, Murphy KC, Sassetti CM, Li H, Farhat MR. Proc Natl Acad Sci U S A. 2026 Oct 27;123(43):e2607261123. doi: 10.1073/pnas.2607261123. Epub 2026 Oct 21. PMID: 42905546

A qualitative evaluation of a STEAM (Science, technology, engineering, arts, and mathematics) peer education intervention on teenagers' knowledge, confidence, and advocacy for HPV vaccine communication.
Gray Brunton C, Macdonald I, Healy C, Firth R, McDermott A, Malone E. Hum Vaccin Immunother. 2026 Dec;22(1):2745405. doi: 10.1080/21645515.2026.2745405. Epub 2026 Oct 28. PMID: 42949617 Free article.

Platelet Factor 4 and Corresponding Antibodies in Atherosclerosis and Cardiovascular Disease.
Bonisoli GL, Wesche J, Schönborn L, Zaninetti C, Friso S, Martinelli N, Thiele T. Hamostaseologie. 2026 Oct 26. doi: 10.1055/a-2977-8288. Online ahead of print. PMID: 42933483

Exosome-Coated Dendrimer Nanogels as a Therapeutic Vaccine for CT Imaging-Guided Chemoimmunotherapy of Pancreatic Cancer.
Li Z, Xiao X, Li Y, Qin M, Xia L, Yang J, He M, Shen M, Shi X. Polym Sci Technol. 2026 Jul 10;2(10):798-813. doi: 10.1021/polymscitech.6c00065. eCollection 2026 Oct 27. PMID: 42960150 Free PMC article.

Enhanced LAMP-based assay for rapid detection of non-vaccine Streptococcus pneumoniae capsular types in meningitis.
Kim DW, Kim EJ, Sakai J, Oguchi H, Chang B, Takano C, Hayakawa S, Hoshino T, Maesaki S, Sugamoto T, Mitarai S, Kilgore PE, Seki M. Microbiol Spectr. 2026 Oct 27:e0153526. doi: 10.1128/spectrum.01535-26. Online ahead of print. PMID: 42937299 Free article.

The mRNA-based RSV vaccine mRNA-1345 induces robust and durable CD4(+) T cell responses against RSV in younger and older adults.
DiPiazza A, Marcisak E, Yu WH, Makrinos D, Kuo HH, Landy J, McGrath S, Chang X, Cavallaro M, Wu C, Essene A, Lin H, Walker L, Carfi A, Oostendorp J, Paris R, Sun Y. Sci Adv. 2026 Oct 23;12(43):eaeh4436. doi: 10.1126/sciadv.aeh4436. Epub 2026 Oct 21. PMID: 42905839 Free PMC article.

Continued presence and functionality of PF4-antibodies 4.5 years after VITT diagnosis.
Meier RT, Manz XD, Luken J, Hofstede-van Egmond S, Corsten M, Kapur R. Blood Cells Mol Dis. 2026 Oct 27;122:103051. doi: 10.1016/j.bcmd.2026.103051. Online ahead of print. PMID: 42966246 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Cultural and structural barriers to HPV vaccine acceptance among young women in the United Arab Emirates.
Langhe R, AlKhatib A, Saber A, Saqr D, Al-Janabi R, Ahmed S, Kelly T, Mahmoud I, Jawdat Barqawi H. PLoS One. 2026 Oct 30;21(10):e0346507. doi: 10.1371/journal.pone.0346507. eCollection 2026. PMID: 42961930 Free PMC article.

Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36 months post-vaccination among boys and girls.
Ionescu IG, Ouakki M, Breton O, Panicker G, Unger ER, Gilca V, Sauvageau C. Vaccine. 2026 Oct 24;92:129107. doi: 10.1016/j.vaccine.2026.129107. Epub 2026 Sep 3. PMID: 42691819 Free article. Clinical Trial.

Adjuvant selection and optimization in the design of an epstein-barr virus-based multi-epitope vaccine against Burkitt lymphoma.
Trimurti J, Pratiwi SE, Asseggaf SNYRS, Ysrafil Y. J Egypt Natl Canc Inst. 2026 Oct 27;38(1):82. doi: 10.1186/s43046-026-00423-1. PMID: 42934362 Free PMC article.

mRNA vaccine encoding multimerized AIV-M2e fused to MHC-II invariant chain motif and Pan-DR epitope confers protection against H9N2 virus in chickens.
Yadav S, Varma A, Jana S, Mondal S, Sharif S, Mallick AI. Vaccine. 2026 Oct 26;95:129280. doi: 10.1016/j.vaccine.2026.129280. Online ahead of print. PMID: 42933243

Incidence, risk factors, and association with vaccination of thrombocytopenia and immune thrombocytopenia (ITP): A scoping review.
Dudley MZ, Ali H, Villaescusa MR, Law B. Vaccine. 2026 Oct 24;92:129120. doi: 10.1016/j.vaccine.2026.129120. Epub 2026 Sep 3. PMID: 42691821

Whole-genome analysis of avian orthoreovirus isolated in Japan reveals genetic divergence from vaccine strains.
Fujimoto Y, Tsunekuni R, Ikeda T, Nakagara K, Chuma T. Virus Genes. 2026 Oct 26. doi: 10.1007/s11262-026-02290-3. Online ahead of print. PMID: 42934443

Application of Fourier transform infrared (FT-IR) spectroscopy to discriminate serotypes of Streptococcus suis.
Massacci FR, Cordovana M, Albini E, Cucco L, Piersanti F, Russo E, Leo P, Baldaccini A, Luppi A, Vio D, Paniccià M, Pezzotti G, Magistrali CF. Vet Res. 2026 Oct 31;57(1):193. doi: 10.1186/s13567-026-01870-3. PMID: 42966872 Free PMC article.

SARS-CoV-2 Vaccination and Attenuation of Breakthrough Infection Severity: A Systematic Global Review and Meta-analysis.
Liu C, Okoli GN, Chen R, Sullivan SG, Cowling BJ. Clin Infect Dis. 2026 Oct 28;83(4):535-545. doi: 10.1093/cid/ciag346. PMID: 42224418

A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Adams C, Hein LD, White LJ, Shah R, Premkumar L, Daag JV, Agrupis KA, Crisostomo MV, Ylade M, Deen J, Lopez AL, de Silva AM. J Infect Dis. 2026 Oct 28:jiag522. doi: 10.1093/infdis/jiag522. Online ahead of print. PMID: 42947633 Free article.

Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins.
Liu C, Ma P, Li J, Li W, Duoji Z, Liu R, Wang Z. Vaccine. 2026 Oct 24;92:129158. doi: 10.1016/j.vaccine.2026.129158. Epub 2026 Sep 11. PMID: 42727398

Molecular epidemiological investigation of bovine coronavirus in some areas of Inner Mongolia and genetic evolution analysis of the S gene.
Sang H, Yin L, Sun J, Meng L, Gao Z, Gai W, Hu Z, Chen L, Song Y, Wen S. Microb Pathog. 2026 Oct 27;222:108881. doi: 10.1016/j.micpath.2026.108881. Online ahead of print. PMID: 42946030

Manganese-Coordinated Rhein Hydrogel as a Vaccine Adjuvant for Synergistically Enhanced Humoral and Cellular Immunity.
Zhang S, Zhou J, Liu Y, Zang H, Teng Z, Sun S, Guo H. ACS Appl Mater Interfaces. 2026 Oct 23. doi: 10.1021/acsami.6c16060. Online ahead of print. PMID: 42925175 Free article.

Antigenic landscape of rabies and related lyssaviruses revealed by cryo-EM.
Callaway HM, Zyla DS, Hastie KM, Harkins SS, Kothalawalage S, Samarasinghe N, Flynn A, Hariharan C, Yin J, Corti D, Bourhy H, Dessain SK, Saphire EO. Cell Rep. 2026 Oct 27;45(10):117993. doi: 10.1016/j.celrep.2026.117993. Epub 2026 Sep 17. PMID: 42758589 Free article.

IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19.
Stoddart L, Johnston TS, Zhou W, El-Diwany R, Leung S, Alachkar N, Wesson RN, Thompson EA, Cox AL, Karaba AH. J Infect Dis. 2026 Oct 27:jiag510. doi: 10.1093/infdis/jiag510. Online ahead of print. PMID: 42937315 Free article.

Practical recommendations for revaccination following BCMA-targeted therapies in adult patients with autoimmune diseases.
Winthrop KL, Calabrese L, Bingham C, Mariette X, Zhou C, Mozaffarian N. Ann Rheum Dis. 2026 Oct 29:S0003-4967(26)00591-1. doi: 10.1016/j.ard.2026.09.014. Online ahead of print. PMID: 42957459

A chimeric PEDV-PDCoV subunit vaccine expressed via baculovirus induced strong immune responses in mice.
Tran MT, Doan TD, Wu HC, Chu CY. Microb Pathog. 2026 Oct 27;221:108899. doi: 10.1016/j.micpath.2026.108899. Online ahead of print. PMID: 42946029

Multiplexed Fc array assays reveal the influence of TLR3 on the Th1-biased humoral response induced in mice following live-attenuated RVFV vaccination.
Divens AM, Mueller Brown K, Barbeau DJ, Fatma F, Allen C, Price DA, Leung DW, Amarasinghe GK, McElroy AK. J Virol. 2026 Oct 29:e0093226. doi: 10.1128/jvi.00932-26. Online ahead of print. PMID: 42954812 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Brazilian version of the Vaccine Trust Gauge for adolescents.
da Silva VM, Lima LM, da Silva MC, Lima JC, Bortolini J, Ratzan SC, Sartori AL, de Freitas BHBM. Vaccine. 2026 Oct 23;95:129270. doi: 10.1016/j.vaccine.2026.129270. Online ahead of print. PMID: 42925770 Free article.

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.
C M, Dymock M, Flanagan KL, Plebanski M, Marshall H, Estcourt MJ, Tjiam MC, Blyth CC, Subbarao K, Nicholson S, Faust SN, Wadia U, Thornton RB, Ellis Z, Williams P, A M, Marsh JA, Foulis C, Salama G, Snelling TL, Richmond P. Vaccine. 2026 Oct 24;92:129034. doi: 10.1016/j.vaccine.2026.129034. Epub 2026 Sep 5. PMID: 42700749 Clinical Trial.

Nanoarchitectonics via emulsion interfacial in situ polymerization for enhanced cross-presentation and antitumor immunity.
Fang Y, Zhang J, Ma Y, Xiang L, Wang Y, Li S, Cheng Y, Li Y, Ma L, Zhang H, Shi Y, Zhao G. J Control Release. 2026 Oct 28:115493. doi: 10.1016/j.jconrel.2026.115493. Online ahead of print. PMID: 42951259

Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies.
Augros J, Rollin J, Benzakine J, Archer E, Billy S, Dupont A, Daniel M, Gruel Y, Pouplard C, Vayne C. Blood Adv. 2026 Oct 27;10(20):7048-7057. doi: 10.1182/bloodadvances.2026020237. PMID: 42685671 Free PMC article.

Economic Evaluations for Malaria Vaccines: A Systematic Review.
Leal CF, López JS, Cuy JA, Viracacha JD, Díaz JA. Value Health Reg Issues. 2026 Oct 27;60:102147. doi: 10.1016/j.vhri.2026.102147. Online ahead of print. PMID: 42945860 Free article.

Digital twins and explainable AI across the vaccine life cycle: from mRNA manufacturing to thermostability, cold-chain logistics, and immunisation services.
Ugwu OP, Okon MB, Ogenyi FC, Ugwu JN, Ugwu CN. Vaccine. 2026 Oct 24;92:129131. doi: 10.1016/j.vaccine.2026.129131. Epub 2026 Sep 7. PMID: 42705167 Review.

Vaccine antibody responses in children with inborn errors of metabolism on protein-restricted diets: an overlooked silent risk?
Yılmazbaş NP, Çakar NE, Yıldız S, Karamanlı G, İdrisoğlu MF. J Pediatr Endocrinol Metab. 2026 Aug 4;39(10):1032-1038. doi: 10.1515/jpem-2026-0219. Print 2026 Oct 26. PMID: 42544393

End-of-season influenza vaccine effectiveness against a(H3N2) and B/Victoria in Beijing, China, 2025/26 season.
Zhang J, Shen Y, Shi W, Ma J, Zhao J, Ma C, Wu D, Wang Y, Lu G, Zhang L, Liu Y, Duan W, Zhang W, Hu X, Xu H, Wang Q, Yang P, Zhang D. Vaccine. 2026 Oct 28;96:129273. doi: 10.1016/j.vaccine.2026.129273. Online ahead of print. PMID: 42950746

Immunogenicity and safety of high-dose versus standard-dose quadrivalent inactivated influenza vaccine in patients living with HIV: a randomized controlled trial.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Laoharattanahirun N, Kiertiburanakul S, Boonnak K, Bruminhent J. Vaccine. 2026 Oct 24;92:129166. doi: 10.1016/j.vaccine.2026.129166. Epub 2026 Sep 17. PMID: 42753388 Clinical Trial.

"Shihu" promote T-cell immunity against breast cancer through bioactive constituent THMB enhancing JAK3-STAT1 signal.
Xia M, Liu XM, Shi XL, Liu FR, Wang XH, Yang MJ, Zhao LX, Zhao YL, Dai Z, Luo XD. J Ethnopharmacol. 2026 Oct 28;369:121888. doi: 10.1016/j.jep.2026.121888. Epub 2026 May 26. PMID: 42202911

Safety first, science second: Healthcare workers' conditional trust and willingness to participate in Lassa fever vaccine trials in Nigeria.
Iliyasu Z, Abubakar MS, Iliyasu BZ, Nass NS, Mande AT. Vaccine. 2026 Oct 24;92:129162. doi: 10.1016/j.vaccine.2026.129162. Epub 2026 Sep 17. PMID: 42753389

Temporal changes in incidence of Shoulder Injury Related to Vaccine Administration (SIRVA) after COVID-19 vaccination.
Kawada H, Shimazaki T, Yamauchi T, Suka M. Vaccine. 2026 Oct 31;96:129304. doi: 10.1016/j.vaccine.2026.129304. Online ahead of print. PMID: 42966041

Development of a subunit vaccine candidate (RBD-HA trimer) provides dual protection against multi-subtype avian influenza viruses and QX-type infectious bronchitis virus.
Zheng Y, Qiao B, Gao Z, Zhang X, Zhao N, Song X, Ping J, Su J. Vaccine. 2026 Oct 24;92:129121. doi: 10.1016/j.vaccine.2026.129121. Epub 2026 Sep 4. PMID: 42696826

A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75.
Oostvogels L, Alhatemi A, De Gussem S, Englev E, Fischer PB, Jacobs B, Johansson-Lindbom B, Kitson G, Waerlop G, Leroux-Roels I. Vaccine. 2026 Oct 24;92:129133. doi: 10.1016/j.vaccine.2026.129133. Epub 2026 Sep 18. PMID: 42759245 Free article. Clinical Trial.

Making inferences with incomplete epidemiological data: a proof-of-concept estimating measles vaccine coverage across Canada.
Hadley L, Milwid RM, Hongoh V, Wasfi R, Kissler SM, Papst I. Vaccine. 2026 Oct 31;96:129261. doi: 10.1016/j.vaccine.2026.129261. Online ahead of print. PMID: 42966042

In silico conservation and HLA-binding profiles of HMPV F and G protein epitopes: implications for universal vaccine development.
Pless LL, Griffith MP, Waggle KD, Coyle H, Spratt A, Beatty AB, Johnson M, Heffelfinger EM, D'Agostino HEA, Susick M, Alicea G, Balasubramani GK, Zimmerman RK, Nowalk MP, Williams J, Harrison LH. Vaccine. 2026 Oct 23;95:129282. doi: 10.1016/j.vaccine.2026.129282. Online ahead of print. PMID: 42914659 Free article.

Recent trial evidence supports enhanced influenza vaccines for older adults: implications for Belgian practice.
Callens S, Peeters M, Van Laethem Y. Acta Clin Belg. 2026 Oct 30:1-10. doi: 10.1080/17843286.2026.2756252. Online ahead of print. PMID: 42961083 Review.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18-64 years.
Mishin VP, Patel MC, Gao R, Grant L, Chesnokov A, Pascua PNQ, Nguyen HT, Champion C, Hegmann KT, Thiese MS, Maguire C, Yoon SK, Merrill LS, Fink RV, Phillips AL, Gangappa S, Wielgosz K, Levine MZ, Dawood FS, Gubareva LV. Vaccine. 2026 Oct 26;95:129281. doi: 10.1016/j.vaccine.2026.129281. Online ahead of print. PMID: 42945702 Free article.

Differences between Canadian parents' attitudes toward routine, influenza, and COVID-19 vaccines for their children, and changes in vaccine hesitancy since the pandemic: A national cross-sectional comparative study.
Humble RM, Reifferscheid L, Gilbert NL, Dubé È, Islam A, MacDonald SE. Vaccine. 2026 Oct 30;96:129300. doi: 10.1016/j.vaccine.2026.129300. Online ahead of print. PMID: 42962460 Free article.

Which changes in adolescents' knowledge, attitudes, and practices following a school-based intervention in France increase HPV vaccination uptake and intentions? A mediation analysis.
Munoz A, Gagneux-Brunon A, Le Duc-Banaszuk AS, Bruel S, Michel M, Gauchet A, Doglioni DO, Barret AS, Raude J, Thilly N, Mueller JE; PrevHPV Consortium. Vaccine. 2026 Oct 24;92:129150. doi: 10.1016/j.vaccine.2026.129150. Epub 2026 Sep 17. PMID: 42753385 Free article. Clinical Trial.

Is the Pennsylvania Measles Outbreak the New Normal?
Anderer S. JAMA. 2026 Oct 30. doi: 10.1001/jama.2026.22533. Online ahead of print. PMID: 42961433

A qualitative examination of factors impacting Black and Latino sexual minority men's vaccination decision-making and experiences: application of the stages of vaccine readiness and action theoretical framework.
Harris OO, Wilson N, Wharton MJ, Andrasik MP, Saberi P. Vaccine. 2026 Oct 30;96:129283. doi: 10.1016/j.vaccine.2026.129283. Online ahead of print. PMID: 42962463 Free article.

Faster waning of immunity to influenza vaccine strains reintroduced into subsequent seasons: A human cohort study.
Cheng C, Chen X, Ge Y, Sung MH, Zuo J, Carlock MA, Hanley HB, Ross TM, Handel A, Shen Y. Vaccine. 2026 Oct 27;95:129258. doi: 10.1016/j.vaccine.2026.129258. Online ahead of print. PMID: 42945703 Free article.

Molecular Dialogue Between Parasites and Hosts: Interactions and Coevolution.
Yang Y, Wang X, Cui X, Tan W. Mol Biochem Parasitol. 2026 Oct 31:111791. doi: 10.1016/j.molbiopara.2026.111791. Online ahead of print. PMID: 42966478 Review.

Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016-17 Through 2024-25.
Meeker JR, Price AM, Martin E, Vaughn I, Wernli KJ, Phillips CH, Gaglani MJ, Raiyani C, Nguyen HQ, King JP, House S, Mills J, Murugan V, Nordstrom L, Saade E, Faryar K, Zimmerman RK, Moehling Geffel K, Walter EB, Bontrager NAB, Chung JR, Flannery B, Ellington S; US Flu VE Network Investigators. J Infect Dis. 2026 Oct 31:jiag538. doi: 10.1093/infdis/jiag538. Online ahead of print. PMID: 42965317

Predictors of severe measles outcomes in hospitalized patients in Jerusalem, 2025.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Gordon O, Oren I, Dorozko SE, Schnapp A, Zahran S, Roda E, Peled N, Moshe AB, Wetzler NJ, Levy R, Hashavya S, Watad S, Aran AA, Pollak U, Cohen LC, Wolf D, Strahilevitz J, Oster Y, Shoob H, Wiener-Well Y, Zeev NB, Averbuch D, Megged O, Brooks R, Tenenbaum A, Mor Z. Clin Microbiol Infect. 2026 Oct 29:S1198-743X(26)00604-X. doi: 10.1016/j.cmi.2026.10.026. Online ahead of print. PMID: 42957093

Nasopharyngeal bacterial carriage in Indonesian children under three years of age in the early post-PCV13 period.
Ciptaningtyas VR, Mujahidah M, Sari RF, Safari D, Hung HCH, Lo SW, Bentley SD, McGee L, Lestari ES, Farida H, de Mast Q, de Jonge MI. Int J Infect Dis. 2026 Oct 31:109218. doi: 10.1016/j.ijid.2026.109218. Online ahead of print. PMID: 42966444 Free article.

Technological resources during the early dissemination of the smallpox vaccine in Europe and the Americas.
Duro-Torrijos JL. Hist Cienc Saude Manguinhos. 2026 Oct 26;33(suppl 1):e2026036. doi: 10.1590/S0104-59702026000100036en. eCollection 2026. PMID: 42961244 Free PMC article.

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.
George B, Singh H, Devoe CE, Chung V, Hosein PJ, Hendifar A, Kim DW, Valerin JB, Bekaii-Saab T, Cardin DB, Hidalgo M, Kasi PM, Leal AD, Pelster M, Fei N, Weekes CD, O'Hara MH, George TJ, Kazmi SM, Mizrahi JD, Nair S, Maiers M, Kheoh T, Amato G, Xavier J, Snyder JP, Milaszewski MH, Cabana-Puig X, Perry JR, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, Wainberg ZA, O'Reilly EM. Nat Med. 2026 Oct 23. doi: 10.1038/s41591-026-04734-7. Online ahead of print. PMID: 42919966

"The past is never dead; it's not even past"☆. From EuCARE experience to future pandemics: Evidence-based lessons for a prepared Europe.
Spaziante M, Cervoni M, Sönnerborg A, Zazzi M, Cozzi-Lepri A, Toscano C, Marchetti G, Jensen B, Naucler P, Girardi E, Kaiser R, Pfeifer N, Gandini S, Abecasis A, Drobniewski F, De Carli G, Incardona F, Vairo F. J Infect Public Health. 2026 Oct 23;19(12):103401. doi: 10.1016/j.jiph.2026.103401. Online ahead of print. PMID: 42945853 Free article.

Mycobacterium tuberculosis suppresses protective Th17 responses during infection.
Zilinskas A, Balakhmet A, Fox D, Ni HM, Agudelo C, Samani H, Stanley SA. Elife. 2026 Oct 23;15:RP110008. doi: 10.7554/eLife.110008. PMID: 42924856 Free PMC article.

Cross-sectional analysis of pneumococcal conjugate vaccine immunity in infants from the community.
Bharathan A, Evans AK. J Public Health (Oxf). 2026 Oct 23:fdag081. doi: 10.1093/pubmed/fdag081. Online ahead of print. PMID: 42912460

Lessons learned from pregnant women's experiences with COVID-19 vaccination in Brazil: A qualitative study.
Maudonnet B, Fesshaye B, Schue JL, Miller E, Silveira C, Bento SF, de Padua KS, Crespo E, Tedesco RP, Matias JP, Tosetto M, Arthur AL, de Souza MEB, Limaye RJ, Singh P, Karron RA, Costa ML, Cecatti JG, Souza RT. Int J Gynaecol Obstet. 2026 Oct 31. doi: 10.1002/ijgo.71466. Online ahead of print. PMID: 42965483

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Multilevel factors associated with human papillomavirus vaccination coverage in Iowa youth: Evidence from a statewide immunization registry.
Hill A, Carrel M, Vu M, Zahnd WE, Janio E, Brandt HM, Sukalski J, Kahl AR, Gufue ZH, Askelson NM. Prev Med. 2026 Oct 28;213:108691. doi: 10.1016/j.ypmed.2026.108691. Online ahead of print. PMID: 42951083

Childhood vaccination timeliness, under-immunization-for-age and measles effective immunity in Peru: a province and birth-cohort analysis of national survey data, 2004-2025.
Rojas JD, Huarachi-Napa CR, Salazar-Buitron SZ, Quillo-Diaz AP, Calderón RI. Vaccine. 2026 Oct 27;95:129286. doi: 10.1016/j.vaccine.2026.129286. Online ahead of print. PMID: 42945700 Free article.

Vaccination coverage, dropout and predictors of schedule-complete vaccination among children aged 0-59 months in Gushegu and Nanumba South districts, northern Ghana: A cross-sectional study.
Konlan M, Bhandari R, Abiwu HAK, Owusu SA, Nunifant A, Adongo SW, Adjei MR, Mahama F, Kubio C, Roberton T. Hum Vaccin Immunother. 2026 Dec;22(1):2753374. doi: 10.1080/21645515.2026.2753374. Epub 2026 Oct 29. PMID: 42956266 Free article.

Evaluating access to COVID-19 vaccines for children and adolescents in North Carolina through community pharmacies, 2021-2023.
Blanchard C, Myers J, McNabb AL, Lee YA, Patel Y, Yemeke T, Savage A, Marciniak MW, Ozawa S. Vaccine. 2026 Oct 24;92:129125. doi: 10.1016/j.vaccine.2026.129125. Epub 2026 Sep 13. PMID: 42732723

Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial.
Thangaraj JWV, Ullas PT, More BD, Shanmugam L, Velusamy S, Gopal D, Ramamoorthy S, Kaliaperumal K, N M M, Arunachalam S, Ramachandran R, Ramakrishnan G, Arunachalam S, J M VV, Anthuvan Valli G, Pugalendhi S, Ramasamy S, T K, Hanifah M, Joy S, Velayudhan A, Egambaram S, Saritha A, Rahi M, Tiwari S, Bondre VP, Murhekar MV; Rabies Vaccine Immunogenicity Trial (RVIT) study group. PLoS Med. 2026 Oct 29;23(10):e1005079. doi: 10.1371/journal.pmed.1005079. Online ahead of print. PMID: 42956084 Free article.

Cost-effectiveness of 13-valent pneumococcal vaccine for children under 5 years of age at high altitude in China: A modeling analysis.
Guo Z, Zhou H, Huang C, Xiong H, Ding R, Xu J, Du X, Liu X, Ma G, Li X, Yuan H, Hu G, A K. Medicine (Baltimore). 2026 Oct 23;105(43):e51156. doi: 10.1097/MD.0000000000051156. PMID: 42937774 Free PMC article.

Integrated genomic, immunoinformatic and experimental evaluation of conserved pneumococcal surface proteins for serotype-independent vaccine development.
Gopalakrishnan S, Jayapal P, Selvamani P, Pavithra A, Ramakrishnan SM, Ravikumar KL, Parthasarathy K, John J. J Appl Genet. 2026 Oct 30. doi: 10.1007/s13353-026-01127-x. Online ahead of print. PMID: 42957866

Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Lu J, Ouyang Z, Huang F, Xie X, Wang X, Wu X, Hu B, Sun J, Jiang M, Sun Y, Liu H, Zhong Y, Lu Q, Dai G, Chen X, Fang S, Jiang Y, Shu Y. Vaccine. 2026 Oct 24;92:129100. doi: 10.1016/j.vaccine.2026.129100. Epub 2026 Sep 6. PMID: 42702143

Contextualizing Shared Clinical Decision-Making Recommendations for Immunization.
Marshall GS, Tan L. J Pediatric Infect Dis Soc. 2026 Oct 30:piag114. doi: 10.1093/jpids/piag114. Online ahead of print. PMID: 42961096

Meeting report of the fifth symposium organized by the coalition to strengthen the HPV immunization community (CHIC): Nairobi, Kenya - advancing sustainable HPV vaccination programs in Africa.
Bolio A, Jennings MC, Burdier R, Jindal S, Kagan S, Karafillakis E, Chaurat E, Njoh AA, Amponash-Dacosta E, Guemgo S, Bakouan RD, Njie M, Jalang'o RE, Wangeci C, Njogu RN, Ndiaye A, Mashiringo C, Morgan C, Vorsters A, Waheed DE. BMC Proc. 2026 Oct 26;20(Suppl 38):42. doi: 10.1186/s12919-026-00403-2. PMID: 42928213 Free PMC article.

Almonds and the optimization of immune responses to influenza vaccination, compared to a control snack, in healthy adults: a randomized controlled trial.
van der Schoot A, Creedon AC, Argomaniz N, Bajka B, Hall WL, Farsi DN, Chrysostomou D, Marchesi JR, Perucha E, Turcanu V, Whelan K, Dimidi E. Am J Clin Nutr. 2026 Oct 26:101596. doi: 10.1016/j.ajcnut.2026.101596. Online ahead of print. PMID: 42933536 Free article.

A TonB-dependent cobalamin receptor as a vaccine target against Acinetobacter baumannii: Structural prediction and murine protection studies.
Raoufi Z, Abdollahi S, Chamchangi MA. Int J Biol Macromol. 2026 Oct 30:155110. doi: 10.1016/j.ijbiomac.2026.155110. Online ahead of print. PMID: 42963026

Chitosan-coated liposomes enhance the immunogenicity and protective efficacy of an oral Streptococcus agalactiae vaccine in Nile tilapia (Oreochromisniloticus).
Hossam-Elden N, Abu-Elala NM, Abd El-Azeem ZMA, Gamal M, El-Saied MA, Marzouk MS. Fish Shellfish Immunol. 2026 Oct 30;180:111802. doi: 10.1016/j.fsi.2026.111802. Online ahead of print. PMID: 42962948

Impact of different MMR vaccination strategies on mumps incidence in Jiangsu, China: A 20-year interrupted time series analysis based on 180,000 cases.
Li M, Yuan D, Wang Z, Xuan Y, Wu Y, Xu Y, Zhu Y, Liu Z, Wu L, Liu Y, Wang B. Vaccine. 2026 Oct 24;92:129156. doi: 10.1016/j.vaccine.2026.129156. Epub 2026 Sep 15. PMID: 42743753

Evaluation of the minipig as an alternative model based on cross-study comparisons with rabbit in mRNA vaccine safety assessment.
Broudic K, Correia M, Laurent S, Elies L, Fant P, Vaure C, Truchot-Limonne N, Desert P. Toxicol Appl Pharmacol. 2026 Oct 28;517:118093. doi: 10.1016/j.taap.2026.118093. Online ahead of print. PMID: 42951042

Newcastle disease virus research: pioneering scientists, landmark discoveries, and virological innovations.
Ul-Rahman A, Munir M. Vet Res Commun. 2026 Oct 24;51(1):19. doi: 10.1007/s11259-026-11585-7. PMID: 42925384 Review.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Development of a novel next-generation multi-epitope vaccine targeting the Guaroa virus glycoprotein precursor through reverse vaccinology.
Asim M, Almatroudi A, Yehia RS, Almustafa H, Aljohani WA, Alrashedi M, Alshuhayb R, Al-Megrin WAI. Naunyn Schmiedebergs Arch Pharmacol. 2026 Oct 31. doi: 10.1007/s00210-026-06044-8. Online ahead of print. PMID: 42963487

A cluster-randomized trial of the school-based 'Superprotegidas' behavioral intervention to improve HPV vaccination uptake in Colombian girls.
Cordoba-Sanchez V, Lemos M, Gaviria-Gómez AM, Sheinfeld Gorin S. Vaccine. 2026 Oct 24;92:129172. doi: 10.1016/j.vaccine.2026.129172. Epub 2026 Sep 17. PMID: 42753387 Free article. Clinical Trial.

Targeted tuberculosis vaccination strategies in the United States: A modeling study.
Rothman JE, Castro KG, Lopman BA, Gandhi NR, Nelson KN. Vaccine. 2026 Oct 24;92:129174. doi: 10.1016/j.vaccine.2026.129174. Epub 2026 Sep 22. PMID: 42771941

Construction of Multigene-Deletion Vibrio parahaemolyticus Strains and Preliminary Evaluation of Their Short-Term Protective Effects in Litopenaeus vannamei.
Liu Z, Che J, Hu S, Fang Q, Xu H, Bao B. Fish Shellfish Immunol. 2026 Oct 27:111801. doi: 10.1016/j.fsi.2026.111801. Online ahead of print. PMID: 42946075

Socioeconomic and health system determinants of zero-dose and under-immunization among children in Zambia: Evidence from the 2024 Demographic and Health Survey.
Mwale M, Chipimo PJ, Phiri A, Sakubita P, Masumbu P, Musonda B, Mwela C, Mwangilwa K, Chipoya M, Gardner PN, Mwansa FD, Gebregiorgis A, Chika M, Matanda K, Masaninga F, Sakala J, Lugala PC. PLOS Glob Public Health. 2026 Oct 30;6(10):e0006618. doi: 10.1371/journal.pgph.0006618. eCollection 2026. PMID: 42961945 Free PMC article.

Evaluation of Andes virus vaccine-derived human antibody for protection in Syrian hamsters: a passive transfer study using phase 1 trial sera.
Hooper JW, Lesko S, Principe L, Josleyn M, Kwilas S, Norris S, Tomashek KM, Paulsen G. EBioMedicine. 2026 Oct 27;133:106535. doi: 10.1016/j.ebiom.2026.106535. Online ahead of print. PMID: 42945893 Free article.

Engineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccine.
Huang S, Madow A, Rudrum J, Peng H, Luu HN, Dong P, Qi J, Belcher AM. Adv Healthc Mater. 2026 Oct 29:e71811. doi: 10.1002/adhm.71811. Online ahead of print. PMID: 42958452

Preparing for Next-Generation Vaccines: Breakthrough Invasive Pneumococcal Disease Patterns Post-PCV13 and Post-PPSV23 in Australia.
Sharifi S, Pelton SI, Yildirim I, Chopra T, Yildirim M. Int J Infect Dis. 2026 Oct 30:109215. doi: 10.1016/j.ijid.2026.109215. Online ahead of print. PMID: 42962990 Free article.

Finding the Goldilocks zone: modulating glycoprotein cleavage and fusogenicity optimizes the efficacy of a candidate Crimean-Congo hemorrhagic fever virus vaccine.
Berrigan J, Monticelli SR, Spealman P, Cohen CA, Batchelor TG, Wang A, McFadden E, Bakken RR, Slough MM, Wirchnianski AS, Mittler E, Cross RW, Geisbert TW, Erasmus JH, Hawman DW, McLellan JS, Herbert

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

AS, Chandran K. mBio. 2026 Oct 29:e0136626. doi: 10.1128/mbio.01366-26. Online ahead of print. PMID: 42954487 Free article.

Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children.
Pant D, Zhang Y, Feaheny F, Kim YC, Shakya M, Shrestha S, Curtis B, Dongol S, Shrestha S, Gehlhaar A, Gurung M, Mujadidi YF, Kelly S, Haque N, Joshi M, Maharjan A, Dahal A, Rijal S, Subhani H, Karkey A, Basnyat B, Shrestha S, Pollard AJ, Liu X; TyVAC Nepal Study Team. Vaccine. 2026 Oct 24;92:129130. doi: 10.1016/j.vaccine.2026.129130. Epub 2026 Sep 5. PMID: 42700746 Free article. Clinical Trial.

Ferritin-displayed engineered sCAR1 nanoparticles as a receptor-decoy antiviral strategy against Coxsackievirus B-associated inflammation.
Zhang X, Li J, Zhang Z, Zheng H, Li H, Zhang Y, Zhao X, Li Y, Wang J, Liao Y, Yu L, Zhao H, Li D, Shi H, Liu L. Antiviral Res. 2026 Oct 27;255:106557. doi: 10.1016/j.antiviral.2026.106557. Online ahead of print. PMID: 42933543

Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice.
Okholm AK, Fougeroux C, Hagen SH, Paludan SR, Nielsen MA, de Jongh WA, Sander AF. Vaccine. 2026 Oct 24;92:129117. doi: 10.1016/j.vaccine.2026.129117. Epub 2026 Sep 5. PMID: 42700748 Free article.

Preparation and immunopotentiating activity of a novel oil-in-water nanoemulsion adjuvant based on trimethyl chitosan.
Liu Z, Guo W, Wang L, Zhao P, Yang S, Zhai D, Fan B, Wang L, Li B. PLoS One. 2026 Oct 27;21(10):e0359159. doi: 10.1371/journal.pone.0359159. eCollection 2026. PMID: 42945266 Free PMC article.

Integrated epidemiological and genomic characterization of respiratory bovine coronavirus in U.S. cattle 2020-2025.
Shah AU, Varga C, Gauger P, Hemida MG. Microbiol Spectr. 2026 Oct 23:e0196126. doi: 10.1128/spectrum.01961-26. Online ahead of print. PMID: 42925059 Free article.

Improving intradermal dosing consistency in mice using a hollow microneedle: A model study with a SARS-CoV-2 mRNA vaccine.
Onishi S, Suzuki Y, Sugimoto K, Otsuka A, Koike N, Shiiba R, Nishimura T, Niitsu T, Hariu W, Tojo T, Yamamoto M, Mori T. Vaccine. 2026 Oct 24;92:129111. doi: 10.1016/j.vaccine.2026.129111. Epub 2026 Sep 5. PMID: 42700750 Free article.

Exposure to natural disasters and vaccination indicators: a systematic review and directions for future research.
Shea B, Shaman J. Vaccine. 2026 Oct 27;95:129277. doi: 10.1016/j.vaccine.2026.129277. Online ahead of print. PMID: 42945701 Free article. Review.

Impact of the HPV vaccination programme on anal HPV infection in gay, bisexual and other men who have sex with men: multi-site enhanced surveillance study in specialist sexual health services in England.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Checchi M, Panwar K, French CE, Mohammed H, Beddows S, Hickman M, Soldan K. Vaccine. 2026 Oct 24;92:129114. doi: 10.1016/j.vaccine.2026.129114. Epub 2026 Sep 6. PMID: 42702144 Free article.

Molecular epidemiology of dengue virus in the Bangka Belitung Islands, Indonesia, during the COVID-19 pandemic.
Dewi BE, Chenderawasi S, Kartika AAA, Khairindra FL, Faridah AT, Ewaldo MF, Fitriani Y, Nainggolan L, Lie T, Erlina L, Sudiro TM, Sjatha F. Infect Genet Evol. 2026 Oct 26:106044. doi: 10.1016/j.meegid.2026.106044. Online ahead of print. PMID: 42933678 Free article.

Immunization with JN.1 spike protein increases the breadth of binding and neutralizing antibodies in Syrian hamsters in an immune-history dependent manner.
Darling TL, Liang CY, Hastings I, Soudani N, Bricker TL, Suthar M, Ellebedy AH, Diamond MS, Boon ACM. Vaccine. 2026 Oct 31;96:129310. doi: 10.1016/j.vaccine.2026.129310. Online ahead of print. PMID: 42966039

["The practice of vaccine inoculation and its dire consequences": a work against the anti-smallpox vaccine in the Portuguese Empire in the early-nineteenth century].
Portugal FDS, Fonseca MRFD. Hist Cienc Saude Manguinhos. 2026 Oct 26;33(suppl 1):e2026037. doi: 10.1590/S0104-59702026000100037. eCollection 2026. PMID: 42961245 Free PMC article. Portuguese.

Syphilis: clinical, diagnostic and therapeutic update.
Blaya Imbernón D, Grau Echevarría A, Díez Recio E, Hernández Bel P. Med Clin (Barc). 2026 Oct 27:107623. doi: 10.1016/j.medcli.2026.107623. Online ahead of print. PMID: 42946614 Review. English, Spanish.

Post-Measles Complications and Mortality in Children under Five Years in Low- and Middle-Income Countries: A Narrative Review.
Jadhav AV, Ghadei S, Sonawane S, Patil P, Birajdar P, Deoshatwar A, Pise K, Nath A, Pawar S, Kumar N. Ann Glob Health. 2026 Oct 26;92(1):105. doi: 10.5334/aogh.5307. eCollection 2026. PMID: 42965144 Free PMC article. Review.

Cost-effectiveness analysis of Mpox control policies: A hybrid rough set-machine learning approach.
Sinha AK, Namdev N, Kushavaha SK. Comput Biol Chem. 2026 Oct 26;126(Pt 2):109502. doi: 10.1016/j.compbiolchem.2026.109502. Online ahead of print. PMID: 42956507

Mapping the Implementation Determinants and Context of Uganda's National Expanded Program on Immunization: A Scoping Review.
Mengistu M, Merucci M, Malande OO, Ezezika O. Health Promot Pract. 2026 Oct 29:15248399261493511. doi: 10.1177/15248399261493511. Online ahead of print. PMID: 42953911 Free article. Review.

mRNA-Guided Therapeutic Strategies in Primary and Metastatic Brain Tumors: Platforms, Targets, and Translational Constraints.
Chirasani S, Freeman H, Baloi D, Karsy M, Pahlevani M. Oncology. 2026 Oct 24:1. doi: 10.1159/ocl/aebag027. Online ahead of print. PMID: 42925534 Free article. Review.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Advanced strategies for enhancing mRNA-lipid nanoparticles stability: molecular insights, stabilization techniques, and clinical applications.
Nurpramesti Prinindya KN, Pokharel S, Mahdi E. Int J Pharm. 2026 Oct 23;706:127561. doi: 10.1016/j.ijpharm.2026.127561. Online ahead of print. PMID: 42918363 Review.

Community knowledge and perceptions of social, ecological, and behavioural risk factors for mpox in Burundi: A nationwide cross-sectional survey.
Nzoyikorera N, Mukama E, Ngendakumana J, Nsengimana F, Ciza R, Uwineza MN, Yombouno AT, Matovu DK, Ayebare RR, Tabaro CA, Nkeshimana A, Diawara I, Fallah MP, Nyandwi J. PLOS Glob Public Health. 2026 Oct 27;6(10):e0007383. doi: 10.1371/journal.pgph.0007383. eCollection 2026. PMID: 42945183 Free PMC article.

Genetic diversity of inclusion body hepatitis-associated fowl adenoviruses in Thailand from 2014 to 2025.
Homklinkaew P, Kulprasertsri S, Phatthanakunanan S, Woramahatthanon K, Witoonsatian K, Panomwan P, Songserm T, Lertwatcharasarakul P. Res Vet Sci. 2026 Oct 24;213:106451. doi: 10.1016/j.rvsc.2026.106451. Online ahead of print. PMID: 42933365

First evidence of an association between alexithymia and reduced humoral immunity following COVID-19 vaccination, independent of insomnia and metabolic factors in healthcare workers.
Petropoulou D, Petropoulou G, Karampela I, Karras SN, Kounatidis DC, Vallianou NG, Papadopoulou A, Muscogiuri G, Dalamaga M. Metabol Open. 2026 Oct 23;32:100515. doi: 10.1016/j.metop.2026.100515. eCollection 2026 Dec. PMID: 42966966 Free PMC article.

Acute multi-organ dysfunction (aMOD): Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
O'Connor C, Jacob ST, Levy JH, Nwagha T, Ramesh D, Munoz FM, Farnon EC, Law B, Ali H. Vaccine. 2026 Oct 30:129264. doi: 10.1016/j.vaccine.2026.129264. Online ahead of print. PMID: 42963301 Free article.

Estimating direct and indirect costs of hospitalised typhoid fever in Indonesia: A multisite healthcare facility and community survey.
At Thobari J, Laksono IS, Haposan JH, Indarti HT, Mulyadi AWE, Anjani A, Watts E, Bines J. PLoS One. 2026 Oct 26;21(10):e0360948. doi: 10.1371/journal.pone.0360948. eCollection 2026. PMID: 42932314 Free PMC article.

Coverage and adherence to the German childhood vaccination schedule: results from the KUNO-Kids health study.
Arede M, Brandstetter S, Beyerlein A, Kabesch M, Köninger A, Apfelbacher C, Böhmer MM. Vaccine. 2026 Oct 24;92:129164. doi: 10.1016/j.vaccine.2026.129164. Epub 2026 Sep 18. PMID: 42759250 Free article.

Risk of Preterm Birth, Congenital Structural Anomalies and Severe Postpartum Hemorrhage After Receipt of NVX-CoV2373 Vaccine During Pregnancy.
Gwak E, Choe YJ, Shin JY, Shah S, Sellers S, Choe SA, Fix J. Pediatr Infect Dis J. 2026 Oct 27. doi: 10.1097/INF.0000000000005455. Online ahead of print. PMID: 42934198

Age-Specific Pertussis Transmission Dynamics and Impact of Immunization Schedule Revision in Hunan, China: Age-Structured Mathematical Modeling Study.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

He Y, Liu Z, Yang Y, Li K, Wang Y, Wu Y, Bu Z, Liu Y, Su Y, Chen Q, Zhao Z, Rui J, Luo K, Chen T. JMIR Public Health Surveill. 2026 Oct 27;12:e104376. doi: 10.2196/104376. PMID: 42944720 Free article.

Topology-Driven X-Shaped DNA as a cGAS Stimulator to Promote Dendritic Cell Activation and Antitumor Vaccine Efficacy.
Li J, Wang X, Wei D, Chen Z, Wang Z, Yu Q, Yang Y, Wang S. Adv Sci (Weinh). 2026 Oct 29:e78563. doi: 10.1002/advs.78563. Online ahead of print. PMID: 42958766 Free PMC article.

Age-specific income losses due to HPV-attributable cancers in Singapore.
Blythe R, Graves N, Iyer NG, Peres MA. PLoS One. 2026 Oct 30;21(10):e0361921. doi: 10.1371/journal.pone.0361921. eCollection 2026. PMID: 42961926 Free PMC article.

Comparative Long-Term Immunogenicity and Boosting of 3-Session Versus 4-Session Intradermal Rabies Post-Exposure Prophylaxis Regimens in Cambodia and Madagascar: The RESIST-3 Study.
Parize P, Touch S, Raharimanga V, Ya N, Worsley-Tonks K, Kergoat L, Thai P, Andriamandimby SF, In S, Dreyfus A, Chan M, Razafindramparany MH, Duong V, Ramiandrasoa R, Peng Y, Cantaert T, Dussart P, Dias de Melo G, Ly S, Randremanana RV, Tarantola A, Bourhy H. Clin Infect Dis. 2026 Oct 28;83(4):e878-e886. doi: 10.1093/cid/ciag368. PMID: 42296188 Free PMC article.

Determinants of Pneumococcal Vaccination Decision-Making Among High-Risk Adults: A Qualitative Study Guided by the Theoretical Domains Framework.
Zhong CC, Chen M, Yim MK, Ng S, Huang J, Wong MCS. Health Sci Rep. 2026 Oct 25;9(10):e73359. doi: 10.1002/hsr2.73359. eCollection 2026 Oct. PMID: 42936154 Free PMC article.

Temporal validation of machine-learning models for shingles vaccine nonvaccination among U.S. adults aged 50 years and older.
Costa NS. Vaccine. 2026 Oct 24;92:129099. doi: 10.1016/j.vaccine.2026.129099. Epub 2026 Sep 3. PMID: 42691823

Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study.
Franzese C, Anderson M, Wu J, Raj A, Coyne M, Biondi S. Expert Opin Drug Deliv. 2026 Oct 28. doi: 10.1080/17425247.2026.2747557. Online ahead of print. PMID: 42948997

Ischemic stroke after bivalent mRNA COVID-19 vaccination and influenza vaccination during the 2022-2023 season: a multi-site self-controlled case series study.
Xu S, Sy LS, Hong V, Farrington P, Glenn SC, Kim S, Ryan DS, Tubert JE, Tong P, Lewin BJ, Tseng HF, Carbayo A, Davis C, Sangha NS, Belongia EA, Sundaram ME, Nelson JC, Daley MF, Klein NP, Fireman B, Haapala J, Hurley LP, Irving SA, Cocoros NM, Weintraub ES, Duffy J, Qian L. Vaccine. 2026 Oct 23;95:129263. doi: 10.1016/j.vaccine.2026.129263. Online ahead of print. PMID: 42914658 Free article.

Ligilactobacillus salivarius inhibits GII.4[P16] human norovirus replication in zebrafish larvae.
Chandran S, Gibson KE. Appl Environ Microbiol. 2026 Oct 30:e0127826. doi: 10.1128/aem.01278-26. Online ahead of print. PMID: 42961044 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Investigation of trends in the research on ferritin-based drug delivery systems *via* a bibliometric and thematic analysis.
Ma J, Tai Z, Li Y, Shen M, Shen C, Xin R, Zhu Q, Chen Z. J Mater Chem B. 2026 Oct 28;14(41):12681-12698. doi: 10.1039/d6tb00466k. PMID: 42825541 Review.

An exploratory study of gut microbiota and humoral immune responses following bacterial ghost administration in rats.
Pradeep A, Mathew AI, Koyyappurath S, Vemula PK, Bhat SG, Narayanan S. Vaccine. 2026 Oct 24;95:129284. doi: 10.1016/j.vaccine.2026.129284. Online ahead of print. PMID: 42925771

Completion of human papillomavirus vaccination and its determinants among adolescents in Southern Ethiopia: a convergent parallel mixed-methods study.
Suwanbamrung C, Sherfa A, Haile D. Korean J Fam Med. 2026 Oct 27. doi: 10.4082/kjfm.26.0105. Online ahead of print. PMID: 42934839 Free article.

The HvfB operon of Pasteurella multocida: An engineered deletion mutant provides cross-protection as an attenuated candidate vaccine strain.
Wang Z, Xu K, Liu S, Zhang Y, Gao Y, Li J, Guo R, He F, Li N, Peng Y. Vet J. 2026 Oct 29;320:106956. doi: 10.1016/j.tvjl.2026.106956. Online ahead of print. PMID: 42957152

Elucidating the role of pre-existing immunity in mucosal lymphoid architectural dynamics following live attenuated influenza vaccination.
Hoen L, Lartey S, Pathirana RD, Cox RJ, Brokstad KA. Vaccine. 2026 Oct 24;92:129139. doi: 10.1016/j.vaccine.2026.129139. Epub 2026 Sep 13. PMID: 42732724 Free article.

Maternal pertussis vaccination uptake and reasons for non-vaccination among pregnant women in the Netherlands: a 5-year retrospective cohort study.
van Vreeswijk-van Donselaar L, Bosma L, Zemouri C, Hoogsteder M. Vaccine. 2026 Oct 24;92:129101. doi: 10.1016/j.vaccine.2026.129101. Epub 2026 Sep 15. PMID: 42743752 Free article.

Multi-pathogen serosurveillance reveals correlated vaccination performance, waning tetanus immunity, and diphtheria boosting in Zambian children.
Sbarra AN, Mutembo S, Carcelen A, Prosperi C, Moss WJ, Truelove S, Winter AK, Bwalya IC, Betha E, Kampamba L, Kabeta E, Chongwe G, Wesolowski A, Takahashi S. Vaccine. 2026 Oct 24;92:129160. doi: 10.1016/j.vaccine.2026.129160. Epub 2026 Sep 17. PMID: 42753386 Free article.

Heterologous adenovirus A2/Leish-Tec vaccination strategy in a murine model of visceral leishmaniasis: Potential canine vaccine with enhanced protection and potent T-cell immunity.
Amado-Gomes AC, Clímaco MC, Cirilo TM, Santos FV, Duval IB, Souza JLN, Cardozo ME, Brito RMM, Coelho EAF, de Oliveira Paes Leme F, Silva RS, Grossi de Oliveira AL, Magalhães LMD, Bueno LL, Bruna-Romero O, Fujiwara RT. Vaccine. 2026 Oct 24;92:129105. doi: 10.1016/j.vaccine.2026.129105. Epub 2026 Sep 11. PMID: 42727397 Free article.

Did the vaccination campaign in Sweden narrow the gap in hospital-registered COVID-19 cases between foreign-born and Swedish-born individuals? A register-based cohort study of adults.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Helgesson M, Tondel M, Nordquist T, Svartengren M. BMJ Open. 2026 Oct 27;16(10):e118005. doi: 10.1136/bmjopen-2026-118005. PMID: 42946353 Free PMC article.

Expression, purification, and diagnostic evaluation of the recombinant matrix protein of peste des petits ruminants virus.
Gul Z, Shah MS, Habib M, Zia MA. Vet Res Commun. 2026 Oct 27;51(1):21. doi: 10.1007/s11259-026-11593-7. PMID: 42945006

Antiviral nanoparticles: mechanisms, biomedical applications and clinical translation toward next-generation therapies.
Perugu R, Sivajyothi S, Wee YJ, Chinni SV, Gopinath SCB, Lebaka VR. Prep Biochem Biotechnol. 2026 Oct 29:1-30. doi: 10.1080/10826068.2026.2748989. Online ahead of print. PMID: 42953933 Review.

Wavelength-Dependent Reduction of Newcastle Disease Virus Infectivity by Femtosecond Laser Irradiation: An In Ovo Proof-of-Concept Study.
El-Gendy AT, Shany SAS, Arafa WM, Mohamed AE, Abdellatif DM, Tamam SM, Mohamed T. Curr Microbiol. 2026 Oct 23;83(12):613. doi: 10.1007/s00284-026-05193-6. PMID: 42920003

Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses.
Odio CD, Aogo RA, Firdous S, Voirin C, Blanco-Rivera S, Lowman KE, Asante N, Broderson Y, Konda K, Hasund CM, Martinez-Perez A, Mpingabo PI, Law M, Jarvis C, Callier V, Hunsberger S, Abad Fernandez M, de Silva A, Kattappuram R, Bhushan G, Yek C, Manning J, Durbin AP, Cohen JI, Weiskopf D, Whitehead SS, Katzelnick LC. Sci Transl Med. 2026 Oct 28;18(873):eaei5117. doi: 10.1126/scitranslmed.aei5117. Epub 2026 Oct 28. PMID: 42950018 Clinical Trial.

Influence of socio-economic inequalities and healthcare organisation on HPV vaccination coverage in both sexes in the Campania region: A population-based study between 2006 and 2023.
Mercogliano M, Montuori P, Bencivenga F, Errico G, Giordano V, Triassi M, Palladino R. Vaccine. 2026 Oct 24;92:129169. doi: 10.1016/j.vaccine.2026.129169. Epub 2026 Sep 20. PMID: 42763966 Free article.

Spatiotemporal distribution of timely measles-containing vaccine coverage among children born in Hebei Province during 2019-2023: a secondary analysis of provincial routine immunisation registry data.
Wang Y, Cong Y, Cui S, Guo Y, Li Y, Li Q. BMJ Open. 2026 Oct 27;16(10):e122115. doi: 10.1136/bmjopen-2026-122115. PMID: 42946350 Free PMC article.

Economic evaluation of the global congenital syphilis prevention benefit of a prospective syphilis vaccine.
Sevilla JP, Burnes D, Bloom DE. BMJ Public Health. 2026 Oct 28;4(4):e004260. doi: 10.1136/bmjph-2025-004260. eCollection 2026. PMID: 42968932 Free PMC article.

Online COVID-19 Misinformation and Infodemic Governance During the Peak Pandemic Period: Scoping Review of Social Media Research From 2020 to 2022.
Liu Y, Yue Z. JMIR Infodemiology. 2026 Oct 29;6:e79434. doi: 10.2196/79434. PMID: 42956193 Free PMC article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Assessment of infant growth and health care utilization following tetanus, diphtheria, pertussis (Tdap) vaccination during pregnancy and lactation.
Palmsten K, Cao J, Vazquez-Benitez G, Ehresmann K, Seburg EM, Kharbanda EO, Clark LR, Li L, Daida Y. Vaccine. 2026 Oct 24;92:129123. doi: 10.1016/j.vaccine.2026.129123. Epub 2026 Sep 6. PMID: 42702141 Free article.

Population-Level Shifts in Cervical Cancer Stage Distribution in the United States Following Human Papillomavirus (HPV) Vaccine Implementation.
Koshy E, Son C. Cureus. 2026 Oct 26;18(10):e118618. doi: 10.7759/cureus.118618. eCollection 2026 Oct. PMID: 42936161 Free PMC article.

Determinants associated with lower HPV vaccination uptake in the school-based program for girls - A follow-up of the Swedish National Immunization Program, 2013-2023.
Appelqvist E, Löf E, Kühlmann-Berenzon S, Ploner A, Lepp T, Sparén P, Lindstrand A, Riesbeck K, Roth A. Vaccine. 2026 Oct 24;92:129083. doi: 10.1016/j.vaccine.2026.129083. Epub 2026 Sep 11. PMID: 42727401 Free article.

Newly developed monoclonal antibodies for marmoset immunosuppression enable KSHV lytic replication and salivary shedding: A promising model for KSHV pathogenesis studies.
Han L, Rodriguez E, Shaw C, Kurian J, Capuano S, Escalante GM, Muniraju M, Jung K, Mutsvunguma LZ, Engelman K, Jung J, Ross CN, Reidel IG, Ogembo JG. PLoS Pathog. 2026 Oct 26;22(10):e1014698. doi: 10.1371/journal.ppat.1014698. eCollection 2026 Oct. PMID: 42932380 Free PMC article.

Navigating HPV vaccination challenges in low-resource settings: Practical strategies for estimating the size of out-of-school girls.
Park S, Rosser EN, Zhang L, Wysong MD, Majidulla A, Terada M, Surkan PJ, Rosen JG, Limaye RJ. PLoS One. 2026 Oct 26;21(10):e0359273. doi: 10.1371/journal.pone.0359273. eCollection 2026. PMID: 42932346 Free PMC article.

Invasive Meningococcal Disease in Hospitalized Children in Argentina, 2020-2024: Clinical, Epidemiologic and Molecular Findings From a Multicenter Active Surveillance Study.
Gentile A, Bakir J, Maydana MN, Morales JC, Ensinck G, Ernst A, Moreira LJ, Melonari PA, Santillán Iturres A, Efron A. Pediatr Infect Dis J. 2026 Oct 23. doi: 10.1097/INF.0000000000005453. Online ahead of print. PMID: 42919450

Construction of a machine learning model for dual-region typing of norovirus RdRp and VP1 based on genomic k-mer features.
Liu Y, Gao J, Peng W, Jiao Y, Xue L. Arch Virol. 2026 Oct 27;171(11):310. doi: 10.1007/s00705-026-06777-0. PMID: 42934417

Novel dengue serotype 4 live virus human challenge: a phase 1 dose optimisation and homologous rechallenge study.
Chua JV, Price A, Sharaf S, Camacho Ortega S, Bernal PJ, Butler L, Koudjra AR, Joshi S, Hardy CSC, Currier JR, Waickman AT, Cairo C, Friberg H, Edelman R, Lyke KE. Lancet Microbe. 2026 Oct 29:101542. doi: 10.1016/j.lanmic.2026.101542. Online ahead of print. PMID: 42956783 Free article.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

A glycoengineered yeast-derived HA1-ferritin nanoparticle vaccine confers protective immunity against H7 avian influenza in chickens.
Liu Y, Shao Y, Su B, Liu P, Huang Y, Zheng H, Xu S, Zhao Y, Li Q, Liao M, Feng S. Vet Res. 2026 Oct 29;57(1):190. doi: 10.1186/s13567-026-01867-y. PMID: 42958438 Free PMC article.

Exploring perceptions of 4CMenB vaccination for gonorrhoea prevention among gay, bisexual and other men who have sex with men and healthcare professionals in England: a qualitative focus group study.
Osman R, Jajja A, Weil B, Doyle T, Berners-Lee B, Lorencatto F, Mohammed H, Campbell H, Ladhani SN, Mandal S, Sabin C, Saunders J, Nicholls EJ. Vaccine. 2026 Oct 30;96:129232. doi: 10.1016/j.vaccine.2026.129232. Online ahead of print. PMID: 42962461 Free article.

Association Between Vaccination Awareness Program Exposure and Full Immunization Coverage Among Mothers in Rural Bangladesh: A Comparative Cross-Sectional Study in Jashore District.
Khatun H, Hossain R, Mia MS. Health Sci Rep. 2026 Oct 27;9(11):e73445. doi: 10.1002/hsr2.73445. eCollection 2026 Nov. PMID: 42948573 Free PMC article.

Toll-like receptor 9 agonist IMO-2125 rapidly reshapes the B-cell receptor repertoire in non-human primates.
Xu Y, Zong X, Wang S, Luo L, Wang IM, Zhou Y. Biochem Biophys Res Commun. 2026 Oct 23;841:154796. doi: 10.1016/j.bbrc.2026.154796. Online ahead of print. PMID: 42962585

Patentes registradas en Patentscope

Estrategia de búqueda: *(Vaccine) AND DP:([23.10.2026 TO 31.10.2026]) as the publication date 26 records.*

1.20260335419Therapeutic Anticancer Neoepitope Vaccine
US - 29.10.2026
Clasificación Internacional A61K 39/00 Nº de solicitud 19725833 Solicitante Nykode Therapeutics ASA Inventor/a Stine Granum

An anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine, are described. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.

2.20260335425VIRUS-LIKE PARTICLE COMBINATION VACCINE COMPRISING INFLUENZA A VIRUS ANTIGEN PROTEIN HA, NA OR M2E5X
US - 29.10.2026
Clasificación Internacional A61K 39/145 Nº de solicitud 19120612 Solicitante UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY Inventor/a Bok Sil JEON

The present invention relates to a virus-like particle combination vaccine comprising influenza A virus antigen protein HA, NA or M2e5x. A recombinant universal influenza-virus-like particle vaccine for protection

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

against infection by influenza A virus (H1N1, H3N2 and H5N1) and influenza B virus (B/Victoria lineages) has been developed by preparing a virus-like particle vaccine expressed by a combination of: hemagglutinin (HA) and neuraminidase (NA) antigen proteins of 2020/2021 influenza viruses of A/Guangdong-Maonan/SWL1536/2019 (H1N1) and A/Hong Kong/2671/2019 (H3N2), which were recently predicted by the World Health Organization (WHO); and heterologous tandem M2e repeat (M2e5x) antigen proteins of conventional human, swine, and avian influenza viruses. The virus-like particle vaccine having high efficacy against various influenza, obtained by developing, on the basis of the present invention, a vaccine exhibiting high immunogenicity, can reduce infection and mortality caused by influenza A and B viruses during a global pandemic.

3.20260337288DC-TARGETING VACCINE AGAINST NIPAH VIRUS INFECTION
US - 29.10.2026
Clasificación Internacional C07K 16/28 Nº de solicitud 19111396 Solicitante INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Inventor/a Yves LEVY

Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein and down-selected epitopes from the Niv F and N proteins (Generation-2 vaccine). Quality controls were performed on vaccine batches. The immunogenicity of both vaccines has been tested in hCD40Tg mice. A dose-dependent IFNg T cell response to the antigen was observed. Three weeks post-boost, specific IgG were detectable in groups immunized with 10 ug of vaccine. B cell responses were markedly improved 1 week post-boost. All samples at week −4 showed a neutralization with an average titer at 1:500. The inventors also demonstrated the potency of an innovative DC-targeting vaccine candidate to prevent NiV-B infection in challenge experiments in an AGM model. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Targeting Nipah virus antigens to professional APCs can be efficiently used as a prophylactic means against a Nipah virus challenge at a lethal dose. Accordingly, the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.

4.20260335432REPLICATION INCOMPETENT HERPES SIMPLEX VIRUS TYPE 1 VIRAL VACCINE
US - 29.10.2026
Clasificación Internacional A61K 39/245 Nº de solicitud 19101316 Solicitante IMMVIRA BIOPHARMACEUTICALS CO., LIMITED Inventor/a Yuanyuan LIU

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

5.WO/2026/224730RECOMBINANT mRNA VACCINE AGAINST SARS-COV-2
WO - 29.10.2026
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/IN2026/050717 Solicitante COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH Inventor/a RAY, Upasana
Most of the vaccines developed against SARS-CoV-2 are based on structural proteins of the virus, especially the spike protein. Antibody dependent enhancement of infection is a common hurdle that comes

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

in the way of vaccine development when structural proteins are used. As mutations accumulate a vaccine that might not be showing antibody dependent enhancement might start showing enhancement of infection based on the mutations that emerge. Also, spike protein is heavily prone to mutations thus requiring next generation vaccines based on mutations that might lead to escape from neutralizing antibodies. In our invention we have targeted a non-structural protein (NSP3) for designing a mRNA based vaccine candidate. As this is based on a non-structural protein we do not anticipate antibody dependent enhancement of infection. We used the MacI domain of this protein. We have added a secretory signal to enable secretion of MacI so that all possible immunological pathways are stimulated. Mice based immunizations showed effective IgG production against MacI that also lasted for extended period time post prime boost immunization.

6.20260335426INFLUENZA VACCINE COMPOSITION FOR PULMONARY DELIVERY
US - 29.10.2026
Clasificación Internacional A61K 39/145 Nº de solicitud 19138434 Solicitante NA VACCINE INSTITUTE Inventor/a Dong Ho KIM

Provided is a pulmonary delivery vaccine composition for preventing or treating influenza virus infection, including a nucleic acid adjuvant and an influenza virus antigen.

7.WO/2026/223818IMMUNOLOGICAL COMPOSITION AND USE THEREOF IN PREPARATION OF VACCINE
WO - 29.10.2026
Clasificación Internacional A61K 39/25 Nº de solicitud PCT/CN2026/093033 Solicitante CANSINO BIOLOGICS INC. Inventor/a ZHU, Tao
An immunological composition and a use thereof in the preparation of a varicella-zoster vaccine, and the varicella-zoster vaccine prepared therefrom. The immunological composition comprises a subunit component and a recombinant adenovirus vector component. The subunit component is a recombinant protein derived from varicella-zoster virus, and the recombinant adenovirus vector component is formed by recombining, by means of genetic engineering, an antigen gene sequence derived from varicella-zoster virus with an adenovirus vector. The immunological composition is administered by inhalation, intramuscular injection, or microneedle administration for immunization, and can effectively elicit humoral immunity, cellular immunity, and mucosal immunity, and is used for preventing or ameliorating infectious diseases caused by varicella-zoster virus.

8.WO/2026/223719MRNA VACCINE FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH HPV INFECTION, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 29.10.2026
Clasificación Internacional C12N 15/37 Nº de solicitud PCT/CN2026/092367 Solicitante NANJING GENELEAP BIOTECHNOLOGY CO., LTD. Inventor/a NOUREDINE, Behloul
An mRNA vaccine for treating or preventing diseases associated with HPV infection, a preparation method therefor, and a use thereof. The mRNA comprises a cap structure, a 5'UTR, E6 and/or E7 coding sequences, a termination codon, a 3'UTR, and polyA that are sequentially linked. The HPV is a combination of HPV types 16, 18, and 58, a combination of HPV types 16, 18, 52, and 58, or a combination of HPV types 16, 18, 31, 45, 52, and 58. The E6 and/or E7 coding sequences encode early proteins E6 and/or E7 of different HPV types. Two adjacent E6 and/or E7 coding sequences are directly linked or linked by means of a linker structure. The mRNA is one of SEQ ID NO. 1 to SEQ ID NO. 11. The above mRNA vaccine not only has a mature preparation process and stable vector properties, but also has good and broad immunogenicity, and therefore has the potential for treating and preventing HPV-related diseases.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

9.WO/2026/222548MULTIVALENT SUBUNIT SALMONELLA VACCINE
WO - 29.10.2026
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/CA2026/050585 Solicitante HIS MAJESTY THE KING IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF AGRICULTURE AND AGRI-FOOD Inventor/a MENASSA, Rima
Vaccine candidates designed to protect poultry against infection with Salmonella enterica serovars include multiple antigenic polypeptide fragments of Salmonella iron acquisition proteins, such as the iron-regulated outer membrane proteins FepA, CirA, IroN and FhuA. The Salmonella antigenic polypeptides are displayed on the surface of protein nanoparticles, such as encapsulin or Brucella spp. lumazine synthase, and can be expressed in plants such as Nicotiana benthamiana.

10.20260335424VACCINE CONSTRUCT AND USES THEREOF
US - 29.10.2026
Clasificación Internacional A61K 39/12 Nº de solicitud 19116913 Solicitante CEVA HAMPTON LIMITED Inventor/a Ian Thompson

The present disclosure relates generally to vaccine constructs comprising a polynucleotide encoding a salmon alphavirus-like particle and uses thereof, including for inducing an immune response against salmonid alphavirus.

11.4831192REKOMBINANTES ANTIGEN GEGEN ZIKA/DENGUE-VIRUS UND IMPFSTOFFZUSAMMENSETZUNG DARAUS UND VERWENDUNG DAVON
EP - 28.10.2026
Clasificación Internacional C07K 14/18 Nº de solicitud 25736397 Solicitante BEIJING BENEWILL TECH DEVELOPMENT CO LTD Inventor/a YAN JINGHUA

A recombinant antigen against Zika/Dengue virus, and a vaccine composition thereof and the use thereof. The recombinant antigen is obtained by means of introducing a specific mutation into the FL fusion loop region and optionally the non-FL fusion loop region of the E protein of a wild-type Zika/dengue virus. By means of introducing the specific mutation, the FL epitope of the recombinant antigen is disrupted, which can avoid inducing the generation of antibodies against the FL epitope; thus, the purpose of reducing or eliminating the ADE effect is achieved. In addition, the recombinant antigen has a correct E protein conformation, has a protein expression level similar to or higher than that of a wild type, and can induce a relatively high titer of specific binding antibodies and neutralizing antibodies in an animal body, so that an effective immune protection can be provided, and good clinical application values and industrialization prospects are achieved.

12.20260335422MODIFIED STREPTOCOCCAL IMMUNOGEN AND USES THEREOF
US - 29.10.2026
Clasificación Internacional A61K 39/09 Nº de solicitud 19486732 Solicitante GPN Vaccines Pty Ltd Inventor/a Chloe Gates

The present disclosure relates to an immunogenic composition comprising an attenuated and/or killed streptococcal bacterial strain comprising a modification that attenuates, reduces or prevents functional expression of LytC (or a homologue thereof). Such a composition may be utilised in a vaccine composition. The immunogenic composition and/or the vaccine composition may be utilised in methods of inducing an immune response to at least one target streptococcal species and/or serotype thereof and/or preventing or

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

reducing an infection and or disease or condition in a subject by at least one target streptococcal species and/or serotype thereof.

13.20260335427SYNTHETIC MODIFIED VACCINIA ANKARA VACCINES TO STIMULATE ORTHOPOX AND MONKEYPOX VIRUS IMMUNITY
US - 29.10.2026
Clasificación Internacional A61K 39/215 Nº de solicitud 18997465 Solicitante CITY OF HOPE Inventor/a Don J. DIAMOND

Disclosed are methods of preventing or treating a coronavirus infection and a poxvirus infection in a subject by administration of a synthetic MVA-based vaccine.

14.2026253909Vaccine compositions and methods of making same
AU - 29.10.2026
Clasificación Internacional Nº de solicitud 2026253909 Solicitante GNT Pharmaceuticals, Inc. Inventor/a MARTINOD, Serge

15.20260335429LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF
US - 29.10.2026
Clasificación Internacional A61K 39/215 Nº de solicitud 19109030 Solicitante FREIE UNIVERSITÄT BERLIN Inventor/a Jakob TRIMPERT

It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome.

16.20260335430METHODS AND MATERIALS FOR USING ADENOVIRUS VECTORS TO IMMUNIZE MAMMALS
US - 29.10.2026
Clasificación Internacional A61K 39/215 Nº de solicitud 19113058 Solicitante Mayo Foundation for Medical Education and Research Inventor/a Michael A. Barry

This document provides methods and materials related to using adenovirus vectors to immunize mammals (e.g., humans). For example, methods and materials for intranasally administering adenovirus vectors (e.g., single-cycle adenovirus vectors) as a heterologous vaccination boost to induce IgG, IgA, and T cell immune responses within a mammal (e.g., a human) that received at least one prior vaccine (e.g., one or more prior mRNA-based vaccines) against the targeted pathogen are provided.

17.WO/2026/223323COMBO VACCINES FOR RESPIRATORY DISEASES
WO - 29.10.2026
Clasificación Internacional A61K 39/295 Nº de solicitud PCT/CN2026/086360 Solicitante SICHUAN CLOVER BIOPHARMACEUTICALS, INC. Inventor/a LIANG, Joshua G
Provided is a combo vaccine against PIV, hMPV and/or RSV, and methods of use thereof.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

18.20260335261METHODS AND COMPOSITIONS FOR CHRONIC INFLAMMATION USING COLCHICINE
US - 29.10.2026
Clasificación Internacional A61K 31/165 Nº de solicitud 19650398 Solicitante Murray and Poole Enterprises, LTD. Inventor/a Michael Riel

Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.

19.4827910GEFRIERGETROCKNETE ZUSAMMENSETZUNG MIT LEBENDEN ATTENUIERTEN PATHOGENEN, VERFAHREN ZUR HERSTELLUNG EINER GEFRIERGETROCKNETEN ZUSAMMENSETZUNG, IMPFSTOFF UND VERFAHREN ZUR IMPFUNG EINES WIRTSTIERS
EP - 28.10.2026
Clasificación Internacional A61K 39/102 Nº de solicitud 24836714 Solicitante INTERVET INT BV Inventor/a ANDERSON ALYSSA

20.WO/2026/222855CLASS OF MRNA-LNP VACCINES WITH POPULATION-WIDE APPLICABILITY AND PREPARATION METHOD THEREFOR
WO - 29.10.2026
Clasificación Internacional A61K 31/7088 Nº de solicitud PCT/CN2025/098444 Solicitante INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES Inventor/a LI, Chuanyun
The present invention relates to a class of mRNA-LNP vaccines with population-wide applicability and a preparation method therefor. Specifically, the present invention relates to a method for constructing a set of novel human de novo originated genes; a gene set constructed by the method; use of a partial coding sequence or a full-length coding sequence of any one gene in the gene set or a molecule for detecting or modulating the expression of the gene in the preparation of a drug for treating a tumor or a diagnostic reagent for diagnosing a tumor; a polynucleotide molecule encoding a protein expressed by any one gene in the gene set, an antigenic fragment thereof, or a variant of the protein or the antigenic fragment; a liposome complex comprising the polynucleotide molecule; use of the liposome complex in the preparation of a vaccine for treating and/or preventing a tumor; and a targeting molecule for modulating the expression of any one gene selected from the gene set.

21.WO/2026/227025PEPTIDE-MHC BINDING
WO - 29.10.2026
Clasificación Internacional C12N 5/10 Nº de solicitud PCT/US2026/025256 Solicitante THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE Inventor/a MARSON, Alexander

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

Provided are compositions and methods for high-throughput identification of peptide- MHC class I binding. An engineered cell having knockouts of HLA-A, HLA-B, HLA-C, TAPI, TAP2, and B2M, and optionally a serine recombinase landing pad, is transfected with a barcoded pcptidc-HLA library. Stable peptide- HLA complexes arc displayed on the cell surface and recruit RNA barcodes to secreted particles via a receptor binding domain. Comparison of barcode abundance in cells versus secreted particles identifies peptide-HLA combinations that form stable complexes, enabling epitope discovery across diverse HLA alleles for vaccine and immunotherapy applications.

22.WO/2026/226415METHODS OF INDUCING ANTI-CANCER IMMUNITY USING CANCER CELL VACCINES
WO - 29.10.2026
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/US2026/023867 Solicitante BRIACELL THERAPEUTICS CORP. Inventor/a WILLIAMS, William V.
The present disclosure provides methods for inducing anti-cancer immunity, especially anti-cancer cytotoxicity, of a subject using a gene-modified cell vaccine. Vaccination strategies, such as priming and boosting regimens, as well as co-administering with an adjuvant, are also provided.

23.4827912ENTWICKLUNG VON IMPFSTOFFEN AUF PNAG-BASIS
EP - 28.10.2026
Clasificación Internacional A61K 39/385 Nº de solicitud 24908908 Solicitante UNIV MICHIGAN STATE Inventor/a HUANG XUEFEI

Provided herein are vaccine composition comprising poly-β-(l-6)-7*N*-acetylglucosamine (PNAG) antigen conjugated to capsid protein carrier, wherein said capsid comprises wild type or native sequence, or at least one mutation, and wherein the PNAG antigen comprises at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 glucosamine monomers, wherein at least one glucosamine monomer is acetylated.

24.4830717SERUMFREIER IMPFSTOFF FÜR INTRAZELLULÄRE PATHOGENE
EP - 28.10.2026
Clasificación Internacional A61K 39/00 Nº de solicitud 26198097 Solicitante INTERVET INT BV Inventor/a KOUMANS JOSEPH

25.20260335423DOMINANT NEGATIVE ANTIGEN APPROACH FOR PROPHYLACTIC AND POST-INFECTION TREATMENT OF SWINE AGAINST AFRICAN SWINE FEVER VIRUS
US - 29.10.2026
Clasificación Internacional A61K 39/12 Nº de solicitud 19038886 Solicitante Thomas MALCOLM Inventor/a Thomas MALCOLM

The disclosed invention pertains and encompasses a composition comprising modified ASFV outer-membrane protein antigen mutants (termed dominant negatives) that exhibit non-binding affinity to RBCs while inducing an antibody-mediated response capable of neutralizing unmodified proteins found on infectious outer-membrane-laden ASFV virions. Additionally, a method for the treatment and/or prevention of ASFV is provided, involving the administration of a dominant negative antigenic composition to animals, thereby averting RBC aggregation caused by the antigen and concurrently treating and/or preventing ASFV. Furthermore, the invention encompasses an ASFV vaccine composition containing the dominant negative antigen as a constituent. Moreover, the invention covers a formulation incorporating these dominant negative antigens in conjunction with antigens derived from capsid-based proteins, which collectively target both lysogenic and lytic viral replication cycles, thereby achieving optimal immune stimulatory protection.

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

26.20260335428PHARMACEUTICAL COMPOSITION COMPRISING HERPES SIMPLEX VIRUS VECTOR US - 29.10.2026
Clasificación Internacional A61K 39/215 Nº de solicitud 19104087 Solicitante Tomoki TODO Inventor/a Tomoki TODO

An object is to provide a virus vector that can be used as a vaccine. A pharmaceutical composition for producing an exogenous polypeptide and inducing an immune response thereto, comprising a herpes simplex virus vector containing a region encoding the exogenous polypeptide and having two or more characteristics selected from the following characteristics (a) to (c):

-
  - (a) the ICP6 gene is deleted or inactivated,
  - (b) the γ34.5 gene is deleted or inactivated, and
  - (c) the α47 gene is deleted or inactivated.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20261023"<=20261031 14 records*

Document ID	Title	Inventor	Applicant Name
US 20260335419 A1	Therapeutic Anticancer Neoepitope Vaccine	Granum; Stine et al.	Nykode Therapeutics ASA
US 20260337288 A1	Dc-Targeting Vaccine Against Nipah Virus Infection	LEVY; Yves et al.	Institut National De La Santé Et De La Recherche Médicale, Assistance Publique-Hôpitaux De Paris (Aphp), Université Paris-Est Créteil Val De Marne
US 20260335429 A1	Live Attenuated Sars-Cov-2 And A Vaccine Made Thereof	TRIMPERT; Jakob et al.	Freie Universität Berlin
US 20260335424 A1	Vaccine Construct and Uses Thereof	Thompson; Ian et al.	Ceva Hampton Limited
US 20260335427 A1	Synthetic Modified Vaccinia Ankara Vaccines to Stimulate Orthopox and Monkeypox Virus Immunity	DIAMOND; Don J. et al.	City Of Hope
US 20260335432 A1	Replication Incompetent Herpes Simplex Virus Type 1 Viral Vaccine	LIU; Yuanyuan et al.	Immvira Biopharmaceuticals Co., Limited

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

US 20260335425 A1	Virus-Like Particle Combination Vaccine Comprising Influenza A Virus Antigen Protein Ha, Na Or M2e5x	JEON; Bok Sil et al.	University-Industry Cooperation Group of Kyung Hee University
US 20260335420 A1	Lyme Disease Vaccines	Plante; Obadiah et al.	ModernaTX, Inc.
US 20260335426 A1	Influenza Vaccine Composition for Pulmonary Delivery	KIM; Dong Ho et al.	Na Vaccine Institute
US 12773444 B2	Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying Treg cells to produce therapeutic vaccine for treatment of diabetes type 1	Trzonkowski; Piotr et al.	Gdanski Uniwersytet Medyczny
US 12773445 B2	Major histocompatibility complex class II-expressing cancer cell vaccine and methods of use for producing integrated immune responses	Odunsi; Kunle et al.	Health Research, Inc.
US 12773450 B2	Coronavirus vaccines, compositions, and methods related thereto	Amara; Rama Rao et al.	EMORY UNIVERSITY
US 12773449 B2	Bacteriophage-based, needle and adjuvant-free, mucosal COVID-19 vaccine	Rao; Venigalla B. et al.	The Catholic University of America
US 12773039 B2	Holder for vaccine guns	Davis; Seth Joseph	Davis; Seth Joseph

Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu



Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS